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Choreatic movement disorders such as Syndenham’s chorea (also known as St Vitus dance) have been 
described since the middle ages [1]. The accompanying symptoms were often associated with possession or a 
form of punishment, invariably leading to stigmatisation. The term “chorea” was first introduced by 
Paracelsus [2], who also disconnected the presumed link between choreatic movements and supernatural 
phenomena [3]. Huntington disease is a choreatic movement disorder with a long historical background [4]. 
Although the symptoms and familial occurrence associated with Huntington disease were described before in 
medical literature, the disease was named after George Huntington who gave a thorough description in his 
1872 paper [5]. Unfortunately and especially due to the rise of eugenics in the first decades of the twentieth 
century, Huntington disease was also subject of severe stigmatization [6]. Currently, patients suffering from 
Huntington disease still perceive discrimination in various ways [7-10]. Obviously, Huntington disease and 
other choreatic movement disorders impose a profound psychological burden on patients and their 
surroundings. Therefore, research into therapeutic interventions that delay or even halt the onset of 
Huntington disease symptoms would be of great benefit. 
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1.1 Huntington disease 
Huntington disease (HD) is an autosomal dominant genetic disorder that mainly affects the brain [11, 12]. 
Symptoms of HD are diverse and include weight loss, psychological and behavioral problems, clinical 
depression and a decrease in voluntarily motor ability [13-17]. HD is a rare disorder with a prevalence 
between 1:10.000 to 1:100.000 varying with the geographical location [18]. The most striking symptom of 
HD is the appearance of involuntarily choreatic movements [5, 12]. In classical cases, HD symptoms first 
appear around mid-life and HD progression usually lasts more than 10 years [12], with the cause of death 
being secondary complications [14, 19-21]. Clinically, the boundary between pre-symptomatic HD gene-
carriers and symptomatic HD patients is diagnosed with the onset of motor symptoms. However, 
psychological and behavioural symptoms often precede clinical HD [22]. Furthermore, it is thought that 
neuronal dysfunction and death precede the onset of clinical symptoms by years [23]. Hence, techniques to 
monitor disease progression before onset are pursued [23-28]. Furthermore, biomarkers capable of monitoring 
HD related changes in an early stage in easy accessible tissue, such as the level of mutant huntingtin protein in 
cerebrospinal fluid [29, 30], or transcriptome analysis of peripheral blood [31, 32] are of particular 
importance. 
1.1.1 The genetics of HD 
After several decades of research, the HD gene was mapped to chromosome 4 [33, 34]. In 1993, the 
responsible mutation was mapped to 4p16.3 and was originally referred to as IT15 (interesting transcript 15) 
[35] while now it is named the huntingtin-gene (HTT). The causative mutation in HD was found to be
expansion of a CAG repeat present in the first exon of HTT, resulting in a mutant huntingtin (htt) protein with
an elongated polyglutamine (polyQ)-stretch [35, 36]. An expansion length of 36 CAG’s or more is considered
mutant [37], and there is an inverse correlation between the age of clinical symptom onset (AoO) and length
of the CAG repeat [37, 38]. Hence, subjects with relatively short expanded CAG repeats (between 36-39
CAG’s) may, or may not show clinical symptoms during their life time. Therefore CAG expansions within
this range are considered to invoke a “reduced penetrance” of the HD phenotype, while CAG repeats of 40 or
more are considered to invoke full penetrance [39]. Correlation between AoO and the CAG-repeat is ~70%,
and AoO can vary several decades between subjects with the same CAG repeat length [40]. Recently, several
genetic factors have been identified that influence the age of disease onset with -1.6, -6.1 or +1.4 years
respectively [41]. Neither AoO, nor CAG repeat length is correlated to the duration or severity of the disease
[42, 43]. The HD phenotype of subjects that are homozygous for the HD mutation does not remarkably differ
from heterozygous subjects [44, 45], which underlines the strong autosomal dominant nature of HD. The
elongated CAG repeat in HD is meiotically unstable, and exhibits anticipation during intergenerational
transmission [46, 47]. Elongation of the CAG-repeat is mainly associated with paternal transmission [46-49].
Maternal transmission of the CAG-repeat length is mainly associated with no effect, or shortening of the
repeat [48, 49], but CAG repeat elongation by maternal transmission is possible [50]. In addition, instability of
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the CAG repeat in post-mitotic neurons was observed in HD mouse models and human HD subjects [51]. 
Meiotic and mitotic instability of CAG repeats have also been reported for other polyQ diseases such as SCA-
1 [52], and SCA-7, [53], but not for Spinal Bulbar Muscular Atrophy (SBMA) [54]. This variability suggests a 
link between CAG stability and the specific gene. CAG repeat instability has been linked with DNA damage 
and repair mechanisms [55, 56], and chromatin remodelling [57]. The general population harbours a certain 
degree of longer, but non-HD associated CAG repeat lengths between 27 and 35 (intermediate CAG-repeat 
length). For example, 5,8% of the general population of British Columbia was found to carry an intermediate 
CAG repeat [58]. Due to intergenerational instability of the CAG-repeat, intermediate CAG-repeats are a risk 
of generating more de novo HD-cases [59]. Some debate regarding the question if intermediate CAG repeats 
could invoke an HD phenotype as well [60, 61] is currently ongoing. However, in these cases it is unclear if 
the observed phenotype is directly linked to the CAG repeat or due to a phenocopy [62], or even an unrelated 
phenotype [63].  
1.1.2 HD pathology 
Post-mortem brain pathology of HD can be divided into five grades (o, i, ii, iii, iv) as defined by VonSattel 
[64]. The primary region of pathology is the striatum (Figure 1A). Striatal degeneration is already apparent on 
MRI-scans in pre-symptomatic HD-gene carriers [65]. Cortical involvement in HD pathology is associated 
with brain weight [66]. On a cellular level, neurons are specifically affected by HD pathology [64]. A subset 
of medium spiny neurons expressing preproenkephalin are preferentially affected early in the disease [67], 
when other neuronal subtypes are spared [68]. There is a large degree of variation in the pattern of neuronal 
loss between HD subjects, which could explain variances in HD “motor” or “mood” phenotypes [69-71]. A 
key pathological hallmark of HD is the presence of protein aggregates (Figure 1B and [72, 73]). The presence 
of aggregates within the cell nucleus was linked to the polyQ-length [74-76]. The exact role of these 
aggregates in HD pathology remains elusive. On one hand, delivery of polyQ aggregates in the nucleus of 
Cos-7 or PC12 cells was pathogenic for the cell [77] and transfer of htt aggregates between neuronal cells is 
possible through tunneling nanotubes [78]. Furthermore, aggregates were shown to sequester other cellular 
proteins such as transcription factors [79, 80], RNA binding proteins [81] and several vesicle-associated 
proteins [82]. This suggests that aggregates are pathologic by interfering with the cellular functions for which 
the co-aggregated proteins are important. However, the selective pattern of striatal degeneration does not 
correlate with the observation that aggregates are predominantly found in cortical tissue and neuronal cells 
that are less vulnerable for mutant htt [83, 84], and it has been shown that aggregate formation can be 
beneficial for cells [85, 86]. 
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1.1.3 Juvenile HD 
In juvenile HD (jHD), HD symptoms occur at an early age. The exact definition of jHD is a matter of debate 
[87], but is generally defined as an AoO lower than 20 years [12]. Juvenile HD is rare with a prevalence 
among the general HD population of approximately 5% [88]. As AoO is influenced by the CAG repeat length 
[40], jHD is associated with exceptionally long CAG repeats of over 55 [12]. Subjects with jHD are more 
likely to exhibit the Westphal-variant of HD clinical symptoms [89] which differ from classical HD, and 
include rigidity and bradykinesia [90-92]. 
Figure 1 – HD Pathology 
(A) Coronal sections of post mortem brain tissue from a late-stage HD patient versus a control subject. Within the HD-
brain, enlargement of the ventricles, severe degeneration of striatal tissue and cortical atrophy is observed. Image
courtesy by Prof. Dr. Raymund A.C. Roos. (B) DAB staining of post-mortem human HD brain tissue. Huntingtin
aggregates indicated by an arrow. Cell nuclei are Nissl counterstained. Image courtesy by Dr. W.M.C. van Roon-Mom.
1.2 The huntingtin protein 
Huntingtin (htt) is a large protein containing 3144 amino acids with a molecular weight of approximately 348 
kD [35]. Evidence suggests full-length htt has an elongated “superhelical” tertairy structure [93]. 
Immunohistochemistry on monkey and human brain indicate that htt is predominantly present within the 
cytoplasm of neurons throughout different brain regions with larger neurons bearing a stronger signal [94-97]. 
Nuclear localization of htt was more abundant with HD subjects [95]. The normal huntingtin protein has many 
functions [98] within several cellular processes including mitosis [99], autophagy [100-102], vesicular 
transport through interaction with the dynein-complex [103-107], regulation of transcription [108, 109], 
transport of TrkB receptors [110] and transport of brain derived neurothropic factor (BDNF) [111]. Huntingtin 
has an anti-apoptotic effect [112], associated with the prevention of Pak2-cleavage [113]. The htt protein is 
essential for embryonic development. Morpholino-mediated knockdown of HTT in Xenopus frogs resulted in 
altered neuronal development and a paralysed phenotype [114]. Double knockout (htt-/htt-) mice did not 
survive past 7.5 days of embryonic development [115]. Interestingly, expression of mutant HTT within (htt-
/htt-) mice rescued embryonic lethality implying that the mutant htt protein retains functionality [116]. This 
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implies a toxic gain-of-function mechanism such as impairment of transcription [117], defective actin 
remodelling [118], mitochondrial functioning [119-121], or endosomic vesicle formation [122] as an 
underlying cause for HD pathology. However, additional effects from loss of normal htt function cannot be 
excluded [123, 124]. 
1.2.1 Expression of normal and mutant huntingtin mRNA and protein 
Huntingtin is expressed in all areas of the brain and all cell types of the brain which does not explain the 
region-specific HD pathology. Using northern blotting, expression of HTT RNA was detected throughout the 
brain and several peripheral human and rat tissues (heart, skeletal muscle, placenta, lung, liver, kidney and 
pancreas) [125]. This ubiquitous expression of HTT RNA was also shown using in situ hybridization on 
human brain tissue [126]. In concordance, the htt protein was also detected throughout the human brain [94, 
97], as well as in several peripheral rat tissues (lung, spleen, kidney, thymus, liver and testes) [94], and in 
human derived myoblasts, fibroblasts and lymphoblasts [127-129]. Knowledge on the expression levels of the 
wild-type versus mutant htt allele in individual subjects is limited and not always consistent. Using qPCR 
against the 5’ UTR, no significant difference between wild-type versus mutant HTT RNA was found in human 
cortical and striatal brain tissue [130]. Also, total HTT mRNA levels in lymphoblastoid cells were the same 
between HD patients and controls [131]. On the other hand, higher levels of mutant HTT mRNA with respect 
to wild-type HTT mRNA were detected with qPCR against SNP rs362307 in human cortical and striatum 
tissue samples [132]. Translation of mutant HTT mRNA into the mutant protein was suggested to be 
upregulated by increased interaction of the MID1-PP2A protein complex with the elongated CAG repeat 
[133]. Two antisense transcripts (HTTAS_v1 and HTTAS_v2) are present at the HTT locus. Expression of 
HTTAS_v1 was shown to reduce HTT transcripts in HEK293 and SH-SY5Y HD cell models. However, levels 
of the HTTAS_v1 antisense transcript is suggested to be reduced in HD subjects [130]. The elongated polyQ-
repeat results in a slightly larger protein, but also invokes atypical structural properties yet to be defined that 
further decrease mobility in an SDS-PAGE gel [134]. Hence, it is possible to separate wild-type htt from 
mutant htt on gel and visualize both forms separately. Western blot results on lymphoblasts indicated that 
longer polyQ repeats resulted in lower expression of the corresponding mutant htt protein [97]. Although no 
statistical analysis was performed by Hu et al, their western blots results on different human-derived HD 
fibroblasts also indicated a lower expression of the mutant htt protein [135]. Western blot studies in post-
mortem human cortex and cerebellar tissue indicated that expression-levels of wild-type and mutant htt are 
comparable [36, 95]. Somatic mosaicism, the presence of genetically distinct cells within the same organism 
[136], was shown in HD mouse models and human HD subjects [51]. Somatic mosaicism can be observed on 
western blot by the presence of multiple protein bands that do not correspond to degradation products or post-















































































































































































































































































































































































































































































































































































































1.2.2 N-terminal huntingtin protein fragments 
The first 17 htt amino acid domain (N17-htt) with the sequence MATLEKLMKAFESLKSF, that precedes the 
polyQ-repeat, plays an important role in HD pathology. N17-htt is associated with htt cellular distribution 
[137-139], has a high conformational flexibility [140] and is important for mutant htt aggregation [141-143]. 
The lysine residues can be either ubiquitinated or SUMOylated, where the latter is associated with HD 
pathology [144, 145]. N17-htt can be phosphorylated at serines S13 and S16, which has been associated with 
a reduction of mutant htt aggregation and a reduced HD phenotype in BACHD mice [146]. Directly after the 
polyQ-repeat, there is a poly proline repeat (polyP) which was suggested to be involved in the sequestering of 
additional proteins to htt aggregates [82]. The mutant htt protein is susceptible to degradation. Caspase-6, a 
protease associated with apoptosis is activated early in HD [147, 148] and the elongated polyQ shortens the 
lifetime of the mutant htt protein, suggesting that the mutant protein is less stable [149]. Also, more 
proteolytic cleavage fragments of htt were shown in HD brain tissue [150], and chapter 4. The importance of 
N-terminal mutant htt protein fragments in HD pathogenesis has been well established. First, results in HD
mouse models that contain full-length or N-terminal htt constructs indicate an increased toxicity for the N-
terminal mutant htt fragments. This was illustrated by the different phenotypes exhibited by the R6/2,
YAC128 and HdhQ150/Q150 HD mouse models. The R6/2 mouse model expresses the first exon of human HTT
with 150 CAGs [151]. The R6/2 model has an average age of symptom onset between 9 to 11 weeks, with
detectable intranuclear htt inclusions appearing after 7 weeks [152]. The YAC128 mouse model that expresses
the full-length human HTT with 128 CAGs [153], shows a much milder HD phenotype. The YAC128 mouse
has a lifespan beyond 18 months, shows an AoO after 3 months, a decrease in brain weight after 9 months and
detectable intranuclear htt aggregates after 12 months. The HdhQ150/Q150 mouse model expresses full-length
murine htt with 150 Q’s [154]. Compared with the R6/2 phenotype after 12 weeks, HdhQ150/Q150 mice reached
a comparable phenotype after 22 months. N-terminal mutant htt fragments not present in aggregates are
mainly monomeric [155] and interfere with cellular processes such as transcription [117] and mitochondrial
functioning [119]. In human post-mortem brain tissue, a difference in striatum-associated N-terminal htt
fragments between controls and HD subjects was detected [150], further indicating an involvement of these
fragments in HD pathology. Several N-terminal htt proteolytic cleavage sites have been identified. Huntingtin
is cleaved between htt amino acids 104-114 as demonstrated in a mouse-rat neuroblastoma-glioma HD cell
model [156, 157], and by matrix metalloproteinase 10 (MMP-10) at amino acid 402 in mouse striatal HD cell-
line Hdh111Q/111Q [158]. Using a 293T (human kidney) cell model of HD, calpain cleavage sites were identified
at htt amino acids 469 and 536 associated with mutant htt toxicity [159]. In addition, experiments with an
HEK293 HD cell model indicated that there are two caspase-3 cleavage sites and one caspase-6 site,
associated with HD pathology present at amino acid positions 513, 552 and 586 respectively [160]. The
caspase 3 site at position 552 was additionally detected in human and mouse brain tissue [161]. Although the
Caspase-3/6 associated N-terminal htt fragments are comparable in size, they behave differently within the
cell. Caspase-6 is activated early in HD [147, 148] and Caspase-6, but not Caspase-3 cleavage was associated
with HD pathology in the YAC128 mouse model [162]. Caspase-6 related N-terminal htt fragments localize
16
within the cell nucleus, whereas N-terminal htt fragments related to caspase-3(a.a.552) cleavage localized within 
the perinuclear region [163]. A comparison between mouse models expressing different N-terminal htt 
fragments showed that the caspase-3(a.a.552) N-terminal htt fragment resulted in a more severe phenotype than 
the caspase-6(a.a.586) N-terminal fragment [164]. In addition, abherrant htt protein fragments can also arise from 
non-proteolytic cleavage-related events. This was shown in the HdhQ150/Q150 mouse model in which fourteen 
different N-terminal htt fragments were identified by western blotting, from which the smallest fragment was 
mapped to the protein part expressed by HTT exon 1 only [165]. Subsequent experiments indicate that the 
source of the exon1-htt fragment is an aberrant splicing event associated with increased binding of the SRSF6 
splicing factor to expanded GAC repeats [166]. Recently, the C-terminal htt fragment not containing the 
polyQ-repeat that arises from htt cleavage was also shown to contribute to HD pathology by invoking 
endoplasmic reticulum (ER) stress through errant interaction with dynamin 1 [167]. 
1.3 HD therapeutic strategies 
Currently, HD treatment is limited to alleviating symptoms resulting in a combination of therapies as each 
symptom mandates a different approach. The search for effective HD therapies is extensive and different 
intervention strategies are assessed [168], including the targeting of peripheral tissues [169], which 
circumvents the need for passing the blood-brain barrier (BBB) [170, 171]. A therapeutic intervention which 
directly targets the pathogenic mutant htt protein is expected to alleviate all HD symptoms, delay disease-
onset and decrease the therapeutic burden on HD patients (Figure 3a). There are several different ways to 
target the mutant htt protein directly: directly lowering the expression levels of mutant htt, modification of the 
mutant htt protein product or blocking pathologically important domains (Figure 3b). Selective lowering of 
mut HTT mRNA translation resulting in less mutant htt protein was demonstrated in human fibroblasts 
derived from HD patients using several types of oligonucleotide constructs including peptide nucleic acid 
(PNA) and locked nucleic acid (LNA) [135], small interfering RNA’s (siRNA) [172, 173] and antisense 
oligonucleotides (AON) [174]. However, specificity for lowering the mutant allele without affecting the wild-
type allele remains an issue with this approach, as lowering of wild-type huntingtin expression is unwanted 
[123]. Modification of the mutant HTT mRNA by means of AON mediated exon-skipping of the 3’part of 
HTT exon 12 was shown to produce a truncated mutant htt protein (htt-∆12) lacking the pathologically 
important caspase-6 cleavage site [175]. Toxicity from this specific htt isoform is not expected as htt-∆12 
occurs naturally [176]. However, protein modification by exon skipping could have unexpected toxic effects 
depending upon the chosen strategy. Moreover, exon-skipping is not specific for the mutant HTT allele. The 
specificity-issue could be addressed by the use of antibodies. Antibodies or immunoglobulins have a high 
specificity for their antigen. There are several classes of classical antibodies (IgA, IgD, IgE, IgG and IgM) of 
which the IgG-class is the most abundant. The IgG class can be further divided into four subclasses, and is a 
“Y”-shaped tetramer of approximately 150 kDa consisting of two heavy chains and two light chains (Figure 
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4a, IgG1). The epitope recognizing domain, responsible for antigen binding, is formed only after combination 
of the correct light-and heavy chain domains. Antibodies are currently utilized against a broad spectrum of 
different pathologies such cancer [177, 178], auto-immune diseases [179], poisoning [180], and they are 
evaluated as a potential therapy against the Ebola virus [181]. However, BBB crossing by antibodies is very 
limited due to their size [182]. It is possible to artificially remove domains from the antibody without affecting 
specificity and affinity for the epitope, thus creating a smaller antibody fragment called a single-chain 
antibody fragment, or scFv, (figure 4a) [183]. An scFv against the htt N17 domain of the htt protein was 
shown to counter mhtt aggregation in a HD cell model [184], suppress HD pathology in a HD drosophilia 
model [185], and to reduce HD pathology in the R6.1 HD mouse model [186]. 
Figure 3 – Therapeutic strategies in Huntington disease 
(A) Alleles for normal HTT (CAG-repeat indicated in green) and mutant HTT (expanded CAG repeat indicated in red) are
first transcribed into pre-messenger RNA (pre-mRNA). Several post-transcriptional modifications of the pre-mRNA,
including splicing of the introns (illustrated in brown) result in messenger RNA (mRNA) which is translated into either
normal (green circle) or mutant (red hexagon) HTT protein. (B) Therapeutic strategies targeting expression levels or
toxicity of the mutant huntingtin protein. Specific lowering of mutant htt protein levels by means of silencing the mutant
HTT gene on the translational level using siRNA or AON. Modification of the mutant huntingtin protein by exon skipping
during post-transcriptional modification. This results in a modified mutant huntingtin protein (green square) with fewer
pathological properties. Neutralization of the mutant huntingtin protein. Antibody (VHH, scFv) binding of pathologically
important domains on the mutant huntingtin protein could neutralize its toxicity.
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1.3.1 VHH antibody fragments
In 1993, the same year as the discovery of the HD-gene, a unique antibody class lacking light chains was 
found in camelids [187]. These heavy chain-only (HCA) antibodies, also found in sharks (called IgNAR, 
[188]) consist of heavy chain dimers (figure 4a). The VHH antibody fragment is derived from the epitope 
recognizing domain of the HCA. The VHH has four framework-regions (FR1-4) that are important for protein 
integrity, and three hyper variable complement determining regions (CDR1-3) that are important for epitope 
selectivity and affinity (figure 4b). Due to the lack of VH-VL interaction, the architecture of the VHH-
domain is different compared with the IgG1-VH-domain [189]. VHH are versatile in their antigen binding 
capabilities. Crystal structures from a VHH in complex with lysozyme show that the CDR3 domain forms an 
extending “loop” allowing the VHH to preferentially bind the enzymatic cleft [190, 191], although VHH are 
also capable of binding flat surfaces using only the CDR3 [192]. In addition, VHH have several other 
advantages compared with conventional IgG antibodies: VHH are 16kD in size and stable [193, 194], VHH 
can be selected easily, intracellular expression of VHH is possible [195, 196], and VHH production in E.Coli 
cells is very effective [197].  
1.3.2  Application of VHH antibody fragments 
Due to their versatility, VHH have several possible medical applications. They are promising as a fast-acting 
antivenom against scorpion (Androctonus australis hector) poisoning [198, 199], or the prevention of 
endotoxin-induced sepsis [200]. VHH directed against the CD4 binding site of the gp120 envelope protein of 
HIV-1 show potential in blocking viral infectious capability [201, 202]. VHH also show potential as 
application against oculopharyngeal muscular dystrophy (OPMD), an autosomal dominant inheritable disease 
similar to HD as it is caused by expansion of an N-terminal polyA repeat of the polyadenylate binding protein 
nuclear 1 (PABPN1) protein resulting in mutant PABPN1 aggregation. Co-expression of an anti PABPN1 
VHH (3F5) was capable of inhibiting mutant PABPN1 aggregation in a HeLa cell model and alleviating the 
phenotype of an OPMD drosophila model [196, 203]. For neuroscience, VHH are of interest because they are 
capable of crossing the blood-brain barrier (BBB) without the help of a carrier under certain circumstances 
[204]. BBB-crossing potential was demonstrated in an in-vitro BBB model for an anti-β amyloid VHH [205]. 
This VHH was shown to be capable of differentially recognizing parenchymal and vascular amyloid deposits 
which will aid in the differential diagnosis of Alzheimer's disease and cerebral amyloid angiopathy [206, 207]. 
VHH might also be applicable as a therapeutic, diagnostic or research tool for other neurological diseases 
such as HD.  
19
Figure 4 – Schematic overview of VHH antibody fragments. 
(A) Immunoglobulin G antibodies (IgG1) consist of two heavy (H) and two light (L) chains. The H and L-chains consist of
one (L) or three (H) constant regions (CL, CH1, CH2 and CH3), and one variable region (VL or VH) where the latter forms
the antigen recognizing domain (dotted square). The scFv antibody fragment contains the IgG antigen recognizing domain
connected by a peptide linker. Heavy chain antibodies (HCA) lack light chains and the CH1-domain from IgG is replaced
by a hinge region that links the antigen recognizing domain (VHH, dotted square) with the CH2-domain. (B) VHH antibody
fragments consist of four framework-regions (FR1, FR2, FR3 and FR4) that are mainly important for structural integrity,
and three hyper-variable complementary determining-regions (CDR1, CDR2 and CDR3) that usually determine the
epitope. (C) Illustration of an M13 phage-VHH particle (P-VHH). The VHH antibody fragment is attached to the PIII subunit
while the corresponding VHH gene is present on the M13 plasmid encapsulated within the M13-phage particle. Western
blot and ELISA with P-VHH as a primary antibody utilise secondary antibodies directed against the PVIII “coat” protein.
1.3.3 Selection of VHH antibody fragments 
Because VHH are expressed from a single gene, cloning and selection of suitable VHH is straightforward. 
VHH can be selected by means of M13 phage-display [208, 209] with the VHH expressed as attachment to 
the pIII-subunit (Phage-VHH, Figure 4C). The construction of a phage display library is illustrated in Figure 
5A and could be performed either from non-immunized (naïve) [195, 196], or immunized [207, 210, 211] 
llama’s (Llama glama). Selection from naïve libraries is expected to yield a higher diversity of binders 
compared with immunized libraries, but affinity of binders is expected to be lower due to the lack of affinity 
maturation against the antigen. It is possible however to enhance VHH binding affinity by artificial maturation 
[212]. The selection of suitable Phage-VHH from a phage display bank consists of one or more subsequent 
rounds of selection in which the antigen could be presented in several ways. Figure 5B shows a 2-round 
selection with antigen-capturing and antigen-panning. 
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Figure 5 – Construction of llama VHH phage display library. 
A B-lymphocytes containing HCA genes are extracted from llama (Llama glama) blood. Pre-immunization with the desired 
antigen (blue) generally results in more high-affinity binders, but lowers diversity of the library (Immunized versus non-
immunized). Linear DNA fragments resulting from a PCR of the VHH genes within HCA are cloned into the M13-phagemid 
vector. The library of M13-VHH phagemid vectors is transformed into Escherichia coli cells for production of the different 
P-VHH particles that make up the llama phage display library. Antigen diversity is illustrated by color. B P-VHH selection
using antigen pre-capture (round 1) involves the desired antigen bound to an antigen-specific IgG coated on a surface.
Washing (wash1) removes any non-binding VHH. VHH binding the desired antigen and non-specific “background” binding
VHH are retained. P-VHH selection using antigen panning (round 2) involves the antigen directly coated on a surface.
Washing (wash2) now removes the “background” binding P-VHH from round 1, and retains P-VHH that bind the desired
antigen that are subsequently eluted. Note: This illustration assumed a 2-round pre-capture/panning selection strategy.
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1.4  Outline of this thesis 
Although the causative mutation for HD has been known for over twenty years and a lot of subsequent 
research has been performed, not much is known about the huntingtin protein in human brain tissue. In 
chapter 2 we have developed a screening-technique to pre-identify identical clone groups selected from 
Llama phage display libraries before sequencing. This technique was used in chapter 3, where we described 
VHH antibody fragments selected against N-terminal htt from a pre-immunized Llama phage display library. 
The selected VHH recognize htt at an N-terminal epitope, are capable binding full-length htt in human brain 
lysate, and might be used as a bio-imaging tool to track full-length htt or N-terminal htt protein fragments. In 
chapter 4 we have looked at the effects of post-mortem delay, tissue preservation and subject variance on the 
profile of N-terminal htt protein fragments in human brain tissue. Our results show that post-mortem delay and 
tissue preservation affect signal strength, but the profile of N-terminal fragments is only minimally affected. 
Subject variance was shown to have a greater effect, underlining the importance of larger subject cohorts. In 
chapter 5 we performed a pilot-study comparing htt aggregation in juvenile HD brain tissue versus adult 
brain tissue using a dot-blot assay. Our results suggest that the dot-blot assay is suitable for quantification of 
htt aggregates, and that htt aggregates in juvenile HD in cortical tissue is more abundant than in striatal tissue. 
In chapter 6 we have assessed the levels of mutant versus wild-type HTT RNA and protein expression. We 
found that expression levels of both mutant htt RNA and protein were equal to or lower than wild-type. We 
also identified HTTAS in a fibroblast cell-line homozygous for HD, suggesting the HD antisense transcript 
levels are not changed when the repeat is expanded. 
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Abstract
Background: Methodologies like phage display selection, in vitro mutagenesis and the
determination of allelic expression differences include steps where large numbers of clones need
to be compared and characterised. In the current study we show that high-resolution melt curve
analysis (HRMA) is a simple, cost-saving tool to quickly study clonal variation without prior
nucleotide sequence knowledge.
Results: HRMA results nicely matched those obtained with ELISA and compared favourably to
DNA fingerprinting of restriction digested clone insert-PCR. DNA sequence analysis confirmed
that HRMA-clustered clones contained identical inserts.
Conclusion: Using HRMA, analysis of up to 384 samples can be done simultaneously and will take
approximately 30 minutes. Clustering of clones can be largely automated using the system's
software within 2 hours. Applied to the analysis of clones obtained after phage display antibody
selection, HRMA facilitated a quick overview of the overall success as well as the identification of
identical clones. Our approach can be used to characterize any clone set prior to sequencing,
thereby reducing sequencing costs significantly.
Background
Phage display libraries consist of small antibody frag-
ments cloned into a display phage vector, allowing effi-
cient antibody screening and production in a bacterial
system [1,2]. Traditional antibodies are composed of a
heavy- and a light-chain that need to recombine in a
tetramer for the formation of a functional antibody.
Because most of these random recombinations will yield
non-functional antibodies, when produced as recom-
binant fragments in E. coli, isolation of effective antibod-
ies demands extremely large phage libraries. Camelidae
have, next to conventional antibodies, dimeric heavy
chain antibodies (HCAb) that lack light chains [3]. The
variable domain of the HCAb (VHH) has a single binding
domain with a specificity and affinity similar to conven-
tional antibodies [4,5]. In a phage display library, each
phage displays a different antigen-binding domain on its
surface. To isolate specific antibodies, phage particles
from a library are bound to an antigen, recovered and
used to infect fresh bacteria. Subsequently, phages go
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tion resulting in an enrichment of binding phages. A per-
fect experiment will ultimately yield groups of phages,
each encoding a different antibody directed against the
starting antigen. The set of phages can be used together as
'polyclonal phages', individual phages as 'monoclonal
phages'. After selection, individual VHH clones are charac-
terized to determine their specificity by ELISA and their
diversity by fingerprinting/sequencing. Although ultimate
identification is done using clone-insert nucleotide
sequencing, pre-sequence fingerprinting is performed to
reduce cost. Phage display clones are usually analysed
using restriction digestion of PCR amplified VHH insert,
followed by agarose gel-electrophoresis [4]. However, this
methodology is time consuming, labour intensive, has
limited resolution and is not effective for the analysis of a
large number of clones.
In the current study, we developed a protocol using high
resolution melt curve analysis (HRMA) to visualise clonal
diversity and study enrichment of clones after VHH-selec-
tion from a llama non-immune phage display library.
Unlike the traditional application for melt curve analysis,
where 1 base pair differences are detected through a
change in melt temperature of a fully base-paired hybrid
and mismatched hybrids, the current study uses differ-
ences in melt curve shape and the Tm of each melt curve
to identify template nucleotide sequence similarities
within a large group of unlike PCR fragments. Similar
melt curve shapes represent similar DNA sequences and
melt curves can be automatically and efficiently grouped
using the available HRMA software.
Results
After two rounds of selection against an epitope spanning
the first 548 amino acids of the huntingtin protein [6], 96
phages were picked and ELISA showed 25 positive and 71
negative wells. An optical density of 0.6 or higher was con-
sidered a positive result while the negative control was less
than 0.1. Clone diversity was investigated using both
HRMA and HinfI restriction digestion of PCR-amplified
clone inserts. As expected, since the PCR fragments had an
average size of 600 bp, HRMA showed a wide range of
melt profiles often containing multiple melting domains
per fragment representing differences in nucleotide
sequence. Representative results from 4 independent
HRMA analyses are shown in Figure 1, a comparison of
the ELISA and HRMA results are shown in Figure 2. Only
the ELISA-positive clones are represented in this figure.
There was a complete agreement of ELISA-positive and
ELISA-negative clones with HRMA analysis. The 25 ELISA-
positive clones belonged to 6 different groups, the largest
Grouping of clones by high resolution melt curve analysis (HRMA)Figure 1
Grouping of clones by high resolution melt curve analysis (HRMA). A) Normalized and temperature shifted melt 
curves for the 25 samples that showed a positive result with ELISA. Samples with differences in their DNA sequences can be 
easily distinguished because of their different shaped melt curves. The different groups as assigned by HRMA are represented 
by different colours. B) Shows the same samples as in A. The differences in melt curve shapes are further analysed by using the 
sample with the highest melting temperature from the normalized and temperature shifted melt curves as a baseline in order 
to cluster samples automatically into groups that have similar melt curves. The different groups as assigned by HRMA are rep-
resented by different colours.Page 2 of 6
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2 clones, and 3 groups contained a unique clone. Of the
remaining 71 clones that showed a negative ELISA, 12
clones could not be analysed by HRMA because of a low
PCR yield and/or low quality melting. The remaining 59
clones could be grouped into 20 different groups, consist-
ing of one large group of 17 clones and three groups of 8,
6, and 4 clones, respectively. The remaining groups all
contained 3 clones or less. All groups identified by restric-
tion digestion fingerprinting were also identified by
HRMA. Groups could overall be confirmed by nucleotide
sequence analysis and PCR fragments were approximately
600 bp in length ranging from 552 to 607 bp with a Tm
of either 85 or 86°C and a G/C content of 53 or 54%. The
most common fragment length was 606 bp with a Tm of
86°C and a G/C content of 54%. Fragments with these
characteristics were present in the majority of groups
assigned by the software. As can be seen in Figure 3,
HRMA even identified one additional group that was not
seen with fingerprinting. However, as can be seen in the
red HRMA group in Figure 3, occasionally, ELISA results
and HRMA results did not agree with restriction digestion
results. Sequencing showed that the red clone with the dif-
ferent digestion pattern was 2 bp different from the other
clones in this HRMA group. These changes were outside
the VHH encoding region and thus did not affect VHH
binding characteristics. However, this 2 bp difference did
change a HinfI restriction site resulting in a different
restriction pattern.
Discussion
HRMA has been used routinely for mutation scanning on
patient samples with small fragments of equal size (up to
400 bp) that differ only 1 or a few nucleotides in sequence
[7]. The temperature at which the probe-template hybrid
melts, distinguishes between fully base-paired hybrids
from mismatched hybrids. In the current study, we devel-
oped a protocol using HRMA to identify clonal origin of
VHH fragments selected from a phage display library as an
alternative for DNA fingerprinting. The protocol uses the
differences in melt curve shape and Tm of each melt curve
to identify template nucleotide sequence similarities
within a large group of samples. Although the software
used for HRMA was originally designed to detect 1 bp dif-
ferences between two small fragments, our results demon-
strate that it is also capable of accurately analysing melt
curves from longer unlike PCR fragments. HRMA is a very
efficient technique to obtain a quick overview and deter-
mine if clone selection was successful. From a successful
selection experiment one expects several recurring clones.
When all clones are different, no enrichment has taken
place and clone selection has probably failed, when all
clones are identical, the success is probably also doubtful.
When the ELISA negative clones contain a large recurrent
set, these clones might either be well-growing but have
low-affinity/are non-specific (not interesting) or high
affinity clones that somehow fail to produce enough VHH
in order to obtain a positive ELISA signal (interesting).
HRMA is also suitable to follow clone selection; initially
one expects all clones to be different, with larger clone sets
emerging in later rounds of selection. When comparing
HRMA to digestion analysis of the VHH fragments, HRMA
analysis is a more sensitive and efficient method to deter-
mine clonal similarity. All groups identified with restric-
tion digestion fingerprinting could also be identified by
HRMA and were overall confirmed by sequence analysis.
Comparison of ELISA results and high resolution melt curve analysis (HRMA)Figure 2
Comparison of ELISA results and high resolution melt curve analysis (HRMA). A) ELISA results for the 96 colonies 
selected from the phage display library. B) The different colours represent the different groups as assigned by HRMA. Only 
results for the ELISA positive clones are shown.Page 3 of 6
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hours to complete after PCR amplification. Furthermore,
it is inexpensive, requiring only PCR, a DNA dye, and
melting instrumentation. In the current study we have
used the LightCycler480 for the final PCR amplification
and melt curve analysis, however, any block cycler can be
used for amplification and the subsequent melt analysis
could then be performed with other high-resolution melt-
ing devices such as the LightScanner (Idaho Technology
Inc, Salt Lake City, Utah). Multiple samples can be ana-
lysed simultaneously (HRMA facilitates analysis of up to
384 clones per microtitre plate) and groups can be
assigned in an automated manner.
Conclusion
HRMA is very efficient to obtain a quick overview and
determine if clone selection was successful. Similar groups
of clones identified by restriction digestion fingerprinting
were also identified by HRMA and were confirmed by
nucleotide sequence analysis. HRMA is suitable for a wide
variety of applications where verification and/or analysis
of clonal diversity is essential, including determining
clone diversity in a single-chain (sc) Fv phage library [8],
analysis of clones obtained after in vitro mutagenesis [9],
cDNA clones to determine allelic expression [10] and
clones to determine methylation status of genomic
regions [11].
Methods
ELISA and restriction digestion
Two consecutive rounds of selection were performed with
a large non-immune VHH library as described previously
[4,5] on the first 548 amino acids of the huntingtin pro-
tein [6]. From this selection, 96 individual colonies were
randomly picked. To assess specific binding to the antigen
of interest, ELISA was performed. In short, all 96 clones
were grown first in 100 μl/well of growth medium (2xTY/
Ampiciline/0,1% Glucose) for 4 hours at 37°C while
shaking (220 rpm). Induction of VHH overproduction
was then performed overnight after adding 20 μl of a 6
mM IPTG solution (in 2xTY/Ampiciline). A 96 well Max-
isorp plate was coated with antigen overnight at 4°C. The
Comparison of ELISA results, high resolution melt curve analysis (HRMA) and restriction digestion analysisFigure 3
Comparison of ELISA results, high resolution melt curve analysis (HRMA) and restriction digestion analysis. 
Shown in the top row of the small square boxes are representative clones from groups as assigned by HRMA. The different 
colours indicate the different groups, and a cross indicates these samples could not be analysed because of a low quality melt 
curve. The second row of boxes indicates the ELISA results. A white box represents a negative ELISA result and an orange box 
indicates a positive ELISA result. The corresponding restriction digestion pattern for each sample is shown in the lower panel. 
HRMA identifies an additional group in the ELISA-positive clones (top panel sample 12,13, 18, 20 and 21) not identified by fin-
gerprint analysis.Page 4 of 6
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and blocked for 30 min at room temperature with 4%
non-fat milk in PBS. After blocking, 50 μl of 4% non-fat
milk/PBS solution was added to each well. Plates contain-
ing the VHH's were spun down at 1200 g and 4°C for 15
minutes. From each well, 50 μl of VHH-containing super-
natant was added to the corresponding well of the Max-
isorp plate. The Maxisorp plate was then incubated for 2
hours at room temperature while shaking (900 rpm).
After incubation the plate was rinsed 3 times with PBST
and 3 times with PBS. For the detection of bound VHH's,
100 μl of a 1:1000 solution of anti-myc antibody (9E10,
Santa Cruz) conjugated to Horse Radish Peroxidase
(HRP) in 4% non-fat milk/PBS was added to each well.
The Maxisorp plate was then incubated for 2 hours at
room temperature while shaking (900 rpm). After incuba-
tion the plate was rinsed 3 times with PBS containing
0.05% Tween20 and subsequently 3 times with PBS. The
reaction was developed by adding an OPD-H2O2 solution
to each well followed by a 35 minutes incubation at room
temperature under dark conditions. Reaction was stopped
by adding 50 μl/well of 1 M H2SO4. Optical densities were
measured at a wavelength of 490 nm using a plate reader
(Biotek, Winooski, USA). To analyse clone inserts, PCR
was performed on all 96 clones on a standard block cycler
(Bio-Rad, Hercules, CA) using 1 μl of overnight culture
with the following primers: M13R 5'-CAG-
GAAACAGCTATGAC-3' and MPE25WB 5'-TTTCTGTAT-
GGGGTTTTGCTA-3'. Amplification was performed in 1×
PCR buffer, 0.7 U FastStart Taq DNA polymerase (Roche,
Mannheim, Germany), 200 μM dNTPs, 1 pmol of each
primer in a reaction volume of 20 μl. Cycling conditions
were 5 min at 95°C followed by 35 cycles of 40 sec at
95°C, 40 sec at 55°C and 1 min at 72°C, followed by a
final incubation of 5 min at 72°C. DNA fingerprint anal-
ysis was performed on 10 μl PCR product digested for 2 hr
at 37°C in a total volume of 20 μl containing, 1× reaction
buffer and 1 U HinfI (Fermentas, Burlington, Canada) and
digests were run on a 3% agarose gel.
High resolution melt curve analysis
Amplification for HRMA was performed on 2 μl of 1:1000
dilutions of previously amplified clones using the same
primers as in the first PCR reaction in a 10 μl reaction vol-
ume containing 1× LightCycler® High Resolution Melting
Master (Roche), 2 mM MgCl2, and 3 pmol of each primer.
All samples were amplified in duplicate in the Light-
cyler®480 (Roche) and this was followed by melt curve
acquisition. Initial denaturation of 10 min at 95°C was
followed by 30 cycles of 10 sec at 95°C, 30 sec at 55°C
and 20 sec at 72°C. After a final extension of 5 min at
72°C, melt curve acquisition started with a hold of 1 min
at 95°C followed by 1 min at 40°C and ramping from
60°C to 98°C at 1°C/sec with 25 acquisitions per °C.
Grouping of the clones was done using the Genescanning
module of the Lightcyler®480 Software Release 1.5.0
(Roche). The sample with the highest melting tempera-
ture was selected from the normalized and temperature
shifted melt curves and used as baseline for the difference
plot analysis. After the software had calculated the groups,
they were checked manually to ensure that samples with
identical melt curves were assigned to their appropriate
groups. Because the software could only assign 8 groups at
once, analysis was done three times. For the second and
third round of analysis, all samples assigned to groups in
the previous rounds were omitted until all samples had
been clustered.
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Abstract Huntington disease is caused by expansion of a
CAG repeat in the huntingtin gene that is translated into an
elongated polyglutamine stretch within the N-terminal
domain of the huntingtin protein. The mutation is thought
to introduce a gain-of-toxic function in the mutant hun-
tingtin protein, and blocking this toxicity by antibody
binding could alleviate Huntington disease pathology.
Llama single domain antibodies (VHH) directed against
mutant huntingtin are interesting candidates as therapeutic
agents or research tools in Huntington disease because of
their small size, high thermostability, low cost of produc-
tion, possibility of intracellular expression, and potency of
blood-brain barrier passage. We have selected VHH from
llama phage display libraries that specifically target the
N-terminal domain of the huntingtin protein. Our VHH are
capable of binding wild-type and mutant human huntingtin
under native and denatured conditions and can be used in
Huntington disease studies as a novel antibody that is easy
to produce and manipulate.
Keywords VHH  Huntington disease  PolyQ 
N-terminal huntingtin  Huntingtin
Introduction
Huntington disease (HD) is caused by expansion of a CAG
repeat within the first exon of the huntingtin gene (4p16.3)
[1]. This mutation results in an expanded polyglutamine
repeat (polyQ) at the N-terminus of the huntingtin protein
(htt), causing HD pathology through a toxic gain-of-func-
tion mechanism [2]. Antibody binding could reduce tox-
icity of the mutant htt protein. Messer et al. showed that a
single chain Fv antibody construct, selected against the first
17 N-terminal htt amino acids was capable of reducing HD
pathogenesis in various HD models [3, 4]. In our study we
make use of llama single domain antibody fragments called
VHH [5]. VHH contain four framework regions (FR1–4)
for structural integrity and three variable complement
determining regions (CDR1–3) that usually determine
epitope binding. VHH have distinctive advantages com-
pared with other antibody classes. VHH are thermostable,
only *16 kD in size and their single domain nature sim-
plifies selection and production [6, 7]. VHH have been
used for diseases such as oculopharyngeal muscular dys-
trophy (OPMD), which shares characteristics with HD.
OPMD is caused by expansion of a triplet repeat in the
PABPN1 gene that encodes for a polyalanine repeat at the
N-terminus of the polyA binding nuclear 1-protein
(PABN1). VHH binding to an a-helical domain of mutant
PABN1 prevented aggregation [8], and alleviated OPMD
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pathology in a drosophilia model [9]. In the current study,
we have selected VHH against the N-terminal domain of
htt from llama phage display libraries. We show that high
resolution melting curve analysis (HRMCA) [10] can
successfully identify identical clones prior to sequencing.
Our VHH can bind both endogenous and purified human
wild-type and mutant htt at an epitope located between
amino acids 49–148 and can co- immunoprecipitate htt
from human HD brain lysates.
Results
Selection of VHH against N-terminal huntingtin
The phage-VHH (P-VHH) display library originated from
llamas pre-immunized with an Escherichia coli produced
N-terminal htt protein fragment consisting of the first 548
amino acids with 46 polyQs. We performed four different
selections; each selection involved two rounds using either
a wild-type or mutant N-terminal htt fragment. Enrichment
of P-VHH after two rounds of selection was similar for
direct coating or pre-capturing of N-terminal htt in the first
round, with the optimal concentration being 5 lg N-ter-
minal htt (Online Resource 1a). P-VHH output numbers of
up to 3 9 104 were obtained. Screening ELISA revealed
that on average, 20 % of selected clones bound htt (Online
Resource 1b). Further screening by HRMCA (Online
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Fig. 1 VHH protein sequences.
iVHH 1–4 were selected from
an immunized llama phage
display library. nVHH was
selected from a non-immunized
llama phage display library.
Underscored amino acid
position differs from iVHH1.
Amino acid positions,
framework (FR, thin line) and
complementary determining
regions (CDR, thick line) are









































































Fig. 2 VHH specificity for N-terminal htt. Assays were performed on
a recombinant N-terminal htt fragment consisting of amino acids
15–378 with a polyQ length of 17 (htt a.a. 15–378 Q17). Positive
control: MAB5492. Negative control: No P-VHH or P-nVHH.
a ELISA on wells with (black bars), or without (white bars)
N-terminal htt. Bars represent mean ELISA signal from two
independent ELISA assays with standard deviation. Each assay was
performed in triplicate. ELISA absorption units are measured at
k = 490 nm. b Western blotting on N-terminal htt. Blots were
performed twice. kDa Molecular weight (kilodalton)
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htt specific VHH, (immune)VHH1-4. These differed by
one, two, or three amino acid substitutions in the CDR1
and CDR2, while the CDR3 was identical (Fig. 1). The
negative control VHH (n-VHH) was selected previously
from a naive llama phage display library [10].
Specificity of monoclonal iVHH for N-terminal
huntingtin
To investigate if the iVHH specifically bind htt, we per-
formed ELISA and western blot analysis on a normal and
mutant N-terminal htt fragment using P-iVHH [11]. ELISA
resulted in a positive signal for all P-iVHH (Fig. 2a, Online
Resource 2a). P-iVHH1, 2 and 3 showed an equally strong
ELISA signal, whereas P-iVHH4 gave a weaker signal. On
western blot, all P-iVHH showed a band that matched the
band obtained with the known htt antibody MAB5492
(Fig. 2b, Online Resource 2b). Western blotting results
were in agreement with ELISA results.
Epitope determination of iVHH on N-terminal
huntingtin
To determine the epitope of our iVHH, we performed
western blotting using three different N-terminal htt frag-
ments. Each fragment had a partially overlapping sequence
with the next fragment (Fig. 3). All fragments were recog-
nized by the 1H6 antibody [12] while 3702–1, that binds htt
at the N-terminal 13 amino acids (Online Resource 3a), only
recognized fragment I. All P-iVHH recognized all fragments
(Fig. 3, Online Resource 3b) indicating that their epitope is
located within the overlapping region of fragments I, II and
III that consists of amino acids 49–148. Finally, western
blotting with monomeric iVHH was performed. VHH were
produced with an average concentration of 1.1 lg/ll. Wes-
tern blotting using iVHH instead of P-iVHH recognized htt
fragments I, II, and III but with less back ground staining.
iVHH detection of endogenous huntingtin in human
HD brain lysates
Next, we analysed if our iVHH were capable of binding
endogenous human htt. We performed immunoprecipita-
tion experiments using monomeric iVHH and post-mortem
human HD brain lysates. Non-specific binding of htt to the
protA-beads without VHH (Fig. 4, –lane) was low.
Immunoprecipitation in the presence of iVHH resulted in
wild-type and mutant full-length htt band on western
blot, while the negative control VHH (nVHH) did not
show a full-length htt band (Fig. 4, Online Resource 4).
This shows that, in concordance with previous ELISA
and western blot results on N-terminal wild-type and
mutant htt fragments, our iVHH recognize both wild-type
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Fig. 3 VHH epitope determination. Western blots performed on no htt (-), htt a.a. 1–148 Q46 (I), htt a.a. 15–378 Q17 (II), and htt a.a. 49–415
(III). Primary antibody indicated below each blot. Blots were performed twice. kDa Molecular weight (kilodalton)





























Fig. 4 Immunoprecipitation of endogenous human htt with VHH.
Western blot analysis of VHH-htt immunoprecipitation complexes.
VHH used for htt immunoprecipitation indicated at top, Input, 10 lg
of brain lysate; –, No VHH. Arrow indicates full-length htt. kDa
Molecular weight (kilodalton). Blot was analysed with 3702-1 anti htt
antibody. Right bracket 39 enlargement of the iVHH3 immunopre-
cipitation result, showing wild-type (wt) and mutant (mut) huntingtin
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immunoprecipitation with iVHH4 was less efficient com-
pared with the other iVHH.
Discussion
To our knowledge, our study is the first in which VHH
have been selected against N-terminal htt protein fragments
from an immunized llama phage display library. Mono-
clonal antibodies are increasingly used as therapeutic
agents [13]. Proof of concept for using antibodies in HD
has been provided [3, 4]. Whilst this is promising, there are
high demands on any therapeutic or imaging antibody.
Because HD is a brain disorder, it is important to cross the
blood–brain barrier (BBB). Some VHH were able to cross
the BBB [14, 15]. Also, VHH diffusion throughout the
brain, and cellular uptake were demonstrated [15].
Although VHH selection from non-immune phage-VHH
libraries is possible [16], selection from immune llama
phage-VHH libraries is expected to yield more high-
affinity binders because of affinity maturation. However,
diversity will be less as affinity maturation selects for the
strongest binder. This is reflected in our results. Our iVHH
share a high degree of sequence homology. This indicates
that the binding epitope of our iVHH is very similar. Our
iVHH bind full-length and N-terminal htt in a native and
denatured conformation. Binding characteristics for
iVHH1-3 were comparable, whereas iVHH4 showed a
lower binding efficiency. This is probably due to a single
amino acid change in iVHH4 at position 55 in CDR2 where
the a-polar alanine was replaced with a polar serine.
Because both alanine and serine have side-chains of com-
parable sizes, it is conceivable that the lower binding
efficiency of iVHH4 is due to a shift from an a-polar to
polar amino acid. The epitope of all iVHH was mapped to
a region between amino acids 49 and 148 downstream of
the polyQ repeat, explaining why our iVHH bind both
wild-type and mutant htt. In this region, htt contains several
domains associated with HD pathogenesis. There is a
proline rich region involved in sequestration of other pro-
teins into htt aggregates [17]. Furthermore, proteolytic
cleavage between amino acids 104 and 114 was linked with
formation of intranuclear aggregates associated with
increased toxicity [12]. Binding of our iVHH in this region
could alleviate HD pathogenesis. However, it has to be
noted that our huntingtin-specific VHH could also block
neuroprotective properties of wild-type htt [18]. Additional
research is needed to assess the therapeutic properties of
our iVHH or their possible applications in HD research.
We have demonstrated the feasibility of using VHH for
immunoprecipitation, eliminating interference by IgG
bands in the subsequent western blot [19]. Furthermore,
since VHH have been used as imaging agent to stain
amyloid-b deposits in vivo in an Alzheimer disease mouse
model [20], our iVHH could be an interesting in vivo
imaging tool in HD models to visualize the htt protein.
Materials and methods
N-terminal htt fragments
A HTT reference sequence with 23 polyQs was used. For
PCR primers see Table 1. PCR products were ligated
directly into the pGEM-T easy vector (Promega, Madison,
WI, USA), digested with NcoI and SalI (Fermentas, St.
Leon-Rot, Germany), and ligated into a NcoI/XhoI (Fer-
mentas) pre-digested pIVEX 1.3 vector. Clones were
confirmed by sequence analysis. Htt protein fragments
were produced with the RTS-100 wheat germ CECF kit (5
PRIME, Gaitersburg, MD, USA) using the ProteoMaster
rapid translation system (Roche). To produce the N-ter-
minal htt 1–148 Q46 protein fragment, the HD1955 pCI
construct consisting of HTT nucleotides 1–1640 [21] was
cloned into a pRP261 vector using the NcoI/SalI restriction
sites, and re-cloned into the pET28 vector using the
BamHI/SalI restriction sites. The HD1955-pET28 construct
was digested with XhoI and self-religated, resulting in the
HD828-pET28 construct. Production and purification were
performed in BL21 codon? E.coli cells as described for
VHH. To prevent aggregation, dialysis was performed in
PBS ? 0.5 % Sarkosyl (Sigma–Aldrich).
VHH selection
Selections were performed as described [16]. The first
selection round involved a direct coating of NUNC maxi-
sorp plates (Thermo fisher Scientific, Rochester, NY, USA)
Table 1 Construction of N-terminal Htt fragments
N-terminal htt fragment Forward primer Reverse primer
a.a. 1–318 (Q17/Q43) TATGGCGACCCTGGAAA GTCGACGAGCAGCACGCCAAGA
a.a. 15–378 (Q17/Q43) CAAGTCCTTCCAGCAGCA GTCGACGGCTCCGGTCACAACA
a.a. 49–415 (no polyQ) GCCGCCTCCTCAGCTTC GTCGACGCCACCAGACTCCTCCTT
a.a. amino acid, Q17/Q43 polyQ stretch, Underscored SalI-site
432 Neurol Sci (2015) 36:429–434
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with 10, 5, or 2.5 lg of antigen, or a pre-capturing of 10 lg
antigen with 2, 1, or 0.5 lg of coated 1H6 antibody (Ab-
nova, Taipei, Taiwan). Phage-VHH (P-VHH) from the first
round were produced and purified as described [22] and
subjected to a second round of selection with 5, 2.5, or 1 lg
of directly-coated antigen. Purified P-VHH were stored at
-20 C in PBS containing 10 % glycerol. TG1 E. coli cells
were infected with phage-VHH from the second selection
round and plated on LB/Agar containing ampicillin. Ninety-
four randomly selected clones were tested as described [10]. As
secondary antibody for the screening ELISA, we used HRP
conjugated mouse anti M13 (GE Healthcare, Bucking-
hamshire, UK). VHH DNA was purified using the Nucle-
ospin Plasmid purification kit (Macherey–Nagel, Duren,
Germany) according to manufacturer’s instructions. DNA
was sequenced using primer M13REV (CAGGAAA
CAGCTATGAC). DNA to protein conversion: http://www.
bioinformatics.picr.man.ac.uk/research/software/tools/seque-
nceconverter.html. VHH sequence alignment: http://www.
ebi.ac.uk/Tools/msa/clustalW2.
VHH production
PCR was performed on M13 plasmid using primers iVHH-
FW (CGGAATTCCTTTAGTTGTTCCA), and iVHH-Rev
(CACATCATCATCACCATCACG), or nVHH-FW (CGCT
GGATTGTTATTACTCGC) and nVHH-Rev (CCTCA
GAACCCAAGACCA). PCR fragments were cloned into
pUR5850 [23] by SfiI and BstEII (Fermentas) digestion and
ligation. Clones were verified by sequence analysis and
transferred into Neb5 E. coli for production. VHH were
purified using the His6-tag with TALON metal affinity resin
(Clontech, Mountain View CA, USA) according to the
manufacturer’s instructions using 50 mM NaPO4, 0.3 M
NaCl, pH7 as wash buffer. Wash buffer with 150 mM
imidazole was used as elution buffer. Pooled eluates were
dialyzed against PBS using Cellu-Sep dialyze-tube MWCO
3500 (Interchim, MontluÇon, France). VHH production was
checked on Coomassie staining (PageBlue, Thermo-Scien-
tific) and western blotting against the VSV-tag. VHH was
quantified with bicinchoninic assay (BCA, Thermo-Scien-
tific). VHH were stored in 5 % glycerol at -20 C.
ELISA
A 96-well NUNC maxisorp plate was coated with 0.1 lg/
well of antigen. Staining was performed using P-VHH
diluted 1:20, followed by HRP conjugated mouse anti M13
(Millipore Billerica, MA, USA). ELISA signal was visu-
alized with o-Phenylenediamine (OPD, Sigma–Aldrich).
Optical density at k = 490 nm was measured using a plate
reader (Biotek, Winooski, USA). The huntingtin-specific
antibody MAB5492 (Millipore) was used as positive
control.
Western blot
N-terminal htt fragments were run on a 10 % SDS-PAGE
gel and proteins were blotted onto nitrocellulose membrane
(#170-4159, Bio-Rad, Hercules, CA, USA). Blots were
blocked with 4 % non-fat milk (Nutricia, Schiphol, The
Netherlands) in TBST. Primary antibodies: 3702-1 (Epit-
omics, Burlinggame, CA, USA), MAB5492 (Millipore),
1H6 (Abnova, Taipei city, Taiwan), P-VHH or 20 ng/ll
VHH. Blots probed with VHH were subsequently incu-
bated with mouse anti VSV (Cell signalling). Secondary
antibodies: HRP conjugated goat anti-mouse, goat anti-
rabbit (Santa-Cruz), or mouse anti-M13 (Millipore). Bands
were detected with Amersham ECL (#RPN 2132, GE
healthcare) and Hyperfilm ECL (#28906837, GE
healthcare).
Immunoprecipitation assay
Human post-mortem brain tissue from the middle temporal
gyrus of a 67 year old female HD subject (CAG1: 15,
CAG2: 42) was obtained with the families full consent and
the ethical approval of the various institutional Ethics
Committees. Post-mortem delay was 9 h. VHH (15 lg)
was bound to 10 ll bed volume of protein A sepharose
beads (GE Healthcare), and incubated for 90 min with
100 lg of post-mortem human HD brain tissue lysate in
PBS. Western blot analysis of the VHH-htt complexes was
performed as described above, where SDS-PAGE was
performed according to [24].
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Electronic supplemental figure 1. Selection of P-iVHH by two rounds of panning 
against wild type N-terminal huntingtin.  
a TG1 E.coli cells infected with P-VHH were diluted as indicated and spotted on agar medium selective 
for presence of P-VHH. Round 1: P-VHH from the llama phage display bank panned against three 
different concentrations of htt a.a. 15-378 Q17. Most P-VHH are recovered using 5 μg of N-term htt 
(indicated in red). Inp 10−6 / −8 = cells infected with whole phage display bank library diluted 106 or 108 
x. Round 2: P-VHH from the most efficient first round selection were enriched and panned for a second
time against htt a.a. 15-378 Q17 at indicated concentrations. Most P-VHH are recovered at a htt
fragment concentration of 5 μg (indicated in blue). - = cells infected with enriched first round P-VHH
selected against a blank well (background). Inp 10−8 = cells infected with whole round 1 P-VHH diluted
108 x. b Screening ELISA of 94 individual P-VHH clones from round 2. There were 13 (14%) ELISA
positive clones (AU490>0.4) detected. c High resolution melting curve analysis (HRMCA) of ELISA
positive clones revealed two groups of similar clones; blue (7 clones) and red (3 clones), and three
unique VHH (green, pink and grey)
48
Electronic supplemental figure 2. Binding of P-VHH to N-terminal Htt fragment with 
elongated polyQ. Assays were performed on a recombinant N-terminal htt fragment consisting of 
amino acids 15 to 378 with a polyQ length of 43 (htt a.a. 15-378 Q43). Anti htt antibody MAB5492 
served as positive control. Assays performed without P-VHH or the non-binding P-nVHH served as 
negative control. a ELISA with P-VHH on wells with (grey bars), or without (white bars) htt a.a. 15-378 
Q43. Bars represent mean ELISA signal from two independent ELISA assays with standard deviation. 
Each assay was performed in triplicate. ELISA absorption units are measured at λ=490nm b Western 
blotting with P-VHH on htt a.a. 15-378 Q43. All blots were performed twice. kDa = running height in 
kilodalton. 
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Electronic supplemental figure 3. Epitope determination of 3702-1 and VHH antibodies.  
a Western blot on five different N-terminal htt fragments: htt a.a. 1 to 318 with wild type (Q17) and 
mutant (Q43) polyQ, htt a.a. 15 to 378 with wild type (Q17) and mutant (Q43) polyQ and htt a.a. 49-415 
without the polyQ. MAB5492 (left bracket) binds all htt fragments. 3702-1 (right bracket) only binds htt 
a.a. 1 to 318 with either the wild type or mutant polyQ. b Epitope determination of P-iVHH1, 3 and 4.
Fragments: I = N-terminal htt fragment with a.a. 1 to 148 with a mutant polyQ (Q46). II = N-terminal htt
fragment with a.a. 15 to 378 with a wild type polyQ (Q17). III = htt fragment with a.a. 49 to 415 without
polyQ stretch. - = no htt fragment. Blot performed with non-binding P-nVHH served as a negative
control. All blots were performed twice.
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Electronic supplemental figure 4. Immunoprecipitation of human full length htt with VHH.  
Input, -, nVHH, iVHH1-4 are shown in figure 4. VHH “X” corresponds to iVHH2 produced from the M13-
vector. VHH produced from the M13-vector are less pure compared with VHH produced from pUR5850, 
hence the band intensity of VHH “X” is lower compared with iVHH2. Because the comparison between 
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Abstract 
Huntington disease is associated with elongation of a CAG repeat in the HTT gene that results in a mutant 
huntingtin protein. Several studies have implicated N-terminal huntingtin protein fragments in Huntington 
disease pathogenesis. Ideally, these fragments are studied in human brain tissue but the use of human brain 
tissue comes with certain unavoidable variables such as post mortem delay, artefacts from freeze-thaw cycles 
and subject-to-subject variation. Knowledge on how these variables affect N-terminal huntingtin protein 
fragments in post mortem human brain is important for a proper interpretation of study results. The effect of 
post mortem delay on protein in human brain is known to vary depending on the protein of interest. In the 
present study, we have assessed the effect of post mortem delay on N-terminal huntingtin protein fragments 
using western blot. We mimicked post mortem delay in one individual control case and one individual 
Huntington disease case with low initial post mortem delay. The influence of subject-to-subject variation on 
N-terminal huntingtin fragments was assessed in human cortex and human striatum using two cohorts of
control and Huntington disease subjects. Our results show that effects of post mortem delay on N-terminal
huntingtin protein fragments are minor. Additionally, we show that one freeze-thaw cycle decreases the
huntingtin western blot signal intensity, but does not introduce additional N-terminal huntingtin fragments.
We conclude that subject-to-subject variation contributes more to variability in N-terminal huntingtin
fragments than post mortem delay.
Introduction 
Huntington disease (HD), is an autosomal dominant neurodegenerative disease that primarily affects the 
striatum and is caused by a CAG repeat expansion in the first exon of the HTT gene [1]. This results in a toxic 
huntingtin protein (htt) with an N-terminally expanded polyQ-stretch [2, 3]. Subsequent studies using HD 
mouse models with comparable polyQ-repeats expressing either N-terminal, or full length htt showed that N-
terminal htt fragments invoke a more severe phenotype [4-6], with smaller fragments inducing the most severe 
phenotype [7, 8]. The htt N-terminal domain contains several proteolytic cleavage sites, some of which have 
been linked to HD pathology [9-12]. Results obtained from different mouse-models are sometimes conflicting. 
YAC128 mouse models expressing full length mutant htt resistant against caspase-3 or caspase-6 cleavage 
suggested that caspase-6 cleavage at amino acid 586 contributes more to HD pathogenesis than caspase-3 
cleavage at amino acids 513 and 552 [13]. On the other hand, murine expression of the N552-htt fragment was 
shown to be more lethal compared with other caspase-associated htt fragments including N586-htt [7]. With 
regards to HD research on N-terminal htt protein fragments, it is important to note that studies in rat, mouse 
and post mortem human brain tissue have indicated that calpain-mediated proteolysis also occurs during post 
mortem delay (PMD) which is the time between death and tissue preservation. In rat brain, PMD-related 
fodrin calpain cleavage fragments were observed [14], and in mouse and human brain tissue PMD-related 
GSK-3 truncation by calpain was demonstrated [15]. Hence, it is important to distinguish biologically relevant 
N-terminal htt fragments from those that are formed during PMD. Available data on N-terminal htt protein
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fragments in human post mortem brain is limited, but also indicates a role in HD pathology. N-terminal htt 
fragments in post mortem human HD striatum differ with post mortem human control striatum [16]. Also, the 
N552-htt fragment that is associated with HD pathology in a HD mouse model was detected in post mortem 
human HD and control brain tissue lysates [11]. Therapeutic strategies involving prevention of formation of 
N-terminal htt fragments are currently pursued [17]. However, extrapolation of results obtained in cell and
animal models to the human brain is difficult. N-terminal htt fragments may vary between different biological
systems [18]. Furthermore, research involving post mortem human brain tissue involves unavoidable variables
that are difficult to control such as PMD, post mortem processing, and interpersonal variation. Effects of PMD
on biological parameters have been well described [19]. In rat brain, synaptic density and vesicles decline
after a PMD of 15hr, with subtle changes on synaptic structure [20]. Binding sites for forskolin, an activator
for adenylate cyclase, were already reduced in rat striatum after a PMD of 4 hours [21]. PMD related effects
vary between different molecules and proteins. No effect of PMD for up to 72 hours was observed for fatty
acid molecules in post mortem human brain tissue [22]. PMD was shown to variously affect different proteins
in mouse CNS [23]. A study on different post mortem human brain samples indicated that levels of synaptic
proteins PSD-95 and syntaxin, but not synaptophysin, decline with PMD [24]. However, care must be taken
when comparing different subjects with comparable PMD because PMD related effects might also vary
between subjects [25, 26]. In the current study, we have assessed effects of PMD, freezing and inter-
individual variation between human subjects on the profile of N-terminal htt fragments on western blot. Our
study shows a small effect of artificially induced PMD on N-terminal htt fragments. Furthermore, one freeze-
thaw cycle already adversely affected the western blot signal for huntingtin in human temporal lobe tissue, but
did not result in the appearance of novel N-terminal htt fragments. Finally, analysis of nine control versus nine
HD subjects matched for age, gender and PMD showed that there was more inter-individual variability in the
profile of N-terminal htt fragments than the variability introduced by PMD.
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Materials and Methods 
Human brain tissue 
Post mortem human cortical and striatal brain tissue from control and HD subjects was obtained from the 
Neurological Foundation of New Zealand Human Brain Bank, Centre for Brain Research, University of 
Auckland. The temporal lobe tissue was obtained 1 hour after surgery on a patient suffering from severe 
epilepsy. Tissue was obtained with the approval by the University of Auckland Human Participants Ethics 
Committee and informed consent from all families. See Table 1 for the complete list of samples with clinical 
information.  
Human brain tissue for analysis of post mortem delay effects. 
To mimic post mortem delay, tissue samples were taken from the main tissue specimen at regular time 
intervals (sampling). During sampling, tissue was left at room-temperature under sterile conditions. 1 ml of 
chilled homogenization buffer (150 mM Sucrose, 15 mM HEPES pH 7.9, 60 mM KCl, 0.5 mM EDTA pH 
8.0, 0.1 mM EGTA pH 8.0, 1% Triton X-100) was added. Tissue was homogenized with a bullet blender 
(Next Advance) for 3 minutes, strength 8 using 0.5 mm stainless steel beads. Homogenized tissue was kept on 
ice for 1 hour and centrifuged cold at full speed for 10 minutes. Supernatant was aliquoted in 100 µl portions, 
snap-frozen and stored at -80˚C. To mimic post mortem delay with and without freeze-thaw cycle, the 
temporal lobe tissue was divided into two halves immediately after obtaining the tissue. One half was 
subsequently sampled, while the other was snap-frozen and stored at -80ºC according to [27] for 11 days 
before sampling. 
Post mortem human brain tissue lysates. 
For every subject, sensory/motor cortex and caudate nucleus tissue was collected separately. Per subject and 
region, 15 slides (thickness: 30 µm) of unfixed tissue were collected on glass slides with a cryostat-microtome 
(LEICA). Grey matter was scraped off, weighed and collected in 0.5 ml eppendorf tubes. 10 µl of chilled 
homogenization buffer was added per µg of tissue with a minimum of 200 µl. Tissue was homogenized with a 
bullet blender (Next Advance) for 3 minutes, strength 8 using 0.5 mm stainless steel beads. Homogenized 
tissue was kept on ice for 1 hour, centrifuged cold at full speed for 10 minutes. Supernatant was aliquoted in 
100 µl portions, snap-frozen and stored at -80˚C. 
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Table 1 – Clinical information 
Type Number Name Age Gender PMD CAG 1 CAG 2 Grade 
HD n.a. HC107 75 M 3 43 19 3 
Control C1 H110 83 F 14 N.A. N.A. n.a.
Control C2 H202 83 M 14 N.A. N.A. n.a.
Control C3 H157 66 M 15 N.A. N.A. n.a.
Control C4 H155 61 M 7 N.A. N.A. n.a.
Control C5 H146 61 M 15 N.A. N.A. n.a.
Control C6 H159 53 M 16.5 N.A. N.A. n.a.
Control C7 H174 59 M 24.5 N.A. N.A. n.a.
Control C8 H130 32 M 13 N.A. N.A. n.a.
Control C9 H200 56 M 23 N.A. N.A. n.a.
HD HD1 HC111 91 F 18 40 15 2 
HD HD2 HC137 83 M 13 41 17 1 
HD HD3 HC133 65 M 14 43 17 3 
HD HD4 HC134 62 M 9 43 18 2 
HD HD5 HC113 58 M 14 44 28 2 
HD HD6 HC120 51 M 15 46 10 2 
HD HD7 HC115 56 M 16 46 16 2 
HD HD8 HC132 32 M 14 47 17 1 
HD HD9 HC119 51 M 15.5 48 17 3 
Age: Age in years at death. F: female, M: male. PMD: post mortem delay in hours. CAG1 = CAG repeat length of mutant 
allele, CAG2 = CAG repeat length of normal allele. N.A. Not assessed. n.a. Not applicable. HD grade according to [28]. 
Average age for control subjects = 61.6 ± 15.5 years, HD subjects = 61.0 ± 17.6 years. Average PMD for control subjects 
= 15.8 ± 5.3 hours, HD subjects = 14.3 ± 2.5 hours. Average CAG repeat length in HD subjects = 44.2 ± 2.7 CAGs (mutant 
allele), 17.2 ± 4.7 CAGs (normal allele). 
Western Blotting. 
100 µg of human brain lysate was used per sample. To detect full length htt, proteins were separated by SDS-
PAGE according to the “shorter CAG repeats” protocol [29]. Proteins were transferred to a nitrocellulose 
membrane (Trans-Blot Turbo Transfer Pack Midi #170-4158, Bio-Rad, Hercules CA, USA) using the Trans-
blot Turbo Transfer system (BioRad) with settings 2.5 A for 10 minutes. Blots were blocked with TBS 
containing 5% (w/v) non-fat milk (Nutricia, Schiphol, The Netherlands), and incubated with primary antibody 
3702-1 (Epitomics, Burlinggame CA, USA) that binds the htt N17 terminus [30]. Secondary antibody goat 
anti rabbit IRDye800 (LI-COR, Lincoln, USA) diluted 1:5000 in TBS containing 5% non-fat milk (w/v). 
Blots were analyzed with the Odyssey infrared imaging system and Odyssey software version 3.0 (LI-COR). 
To detect htt fragments, proteins were separated by SDS-PAGE by running at 40 mA constant through the 
stacking gel and at 50 mA constant through the 10% separating gel alongside a protein size marker 
(PageRuler, Thermo Fisher, St Leon-Rot, Germany). Proteins were blotted onto either a nitrocellulose 
membrane for Control versus HD subjects (Trans-Blot Turbo Transfer Pack Midi #170-4158, Bio-Rad, 
Hercules CA, USA), or a PVDF-membrane for post mortem delay samples (Trans-Blot Turbo Transfer Pack 
Midi #170-4157), using the Trans-Blot Turbo Transfer System (Bio-Rad) with settings 1.0 A for 30 minutes. 
Blots were blocked with TBS containing 5% non-fat milk (Nutricia). For nitrocellulose-blots, primary 
incubation was performed with antibodies 3702-1 (Epitomics) and mouse anti β-actin. Secondary incubation 
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was performed with goat anti rabbit IRDye800 (LI-COR) and goat anti mouse IRDye680 (LI-COR). All 
antibodies were diluted 1:5000 in TBS containing 5% non-fat milk (Nutricia). Blots were analysed with the 
Odyssey reader and viewed using the Odyssey software version 3.0 (LI-COR) with the linear manual 
sensitivity set at 5, or 6 if blot was viewed at “high sensitivity”. For PVDF-blots, primary incubation was 
performed with antibody 3702-1 (Epitomics) diluted 1:1000. Secondary incubation was performed with a 
Goat anti Rabbit antibody conjugated with Horse Radish Peroxidase (Santa Cruz) diluted 1:10.000. Blots were 
visualized using ECL+ substrate (#32132, ThermoFisher Scientific), and Hyperfilm ECL (#28906837, GE 
healthcare). For the β-actin loading control, blots were stripped, re-blocked and incubated with mouse β-actin 
diluted 1:1000, followed by a Goat anti Mouse antibody conjugated with Horse Radish Peroxidase (Santa 
Cruz) diluted 1:10.000. Densitometric analysis was performed with image J. Intensities of relevant bands were 
reported as percentages of the total htt signal within the associated lane. Statistical significance (n=4) between 
timepoints was calculated in Excel using a paired T-test (two sided). 
58
Results 
Two wild-type N-terminal htt fragments increase with artificial PMD in control temporal lobe 
tissue.  
To assess the effect of PMD on N-terminal htt fragments, we obtained human control temporal lobe tissue one 
hour post-surgery. One half was stored at -80ºC and the other half was sampled at regular time-intervals to 
mimic PMD (artificial PMD). Western blot analysis with an antibody that binds huntingtin at the N-terminal 
end showed no change in the full length htt signal, and a subtle gradual increase in band intensity compared 
with T=0 was observed for N-terminal htt fragments of 50 kDa (1,49% ± 1,12% on average), and 65 kDa 
(4,01% ± 1,53 on average) over an eight-hour time period (Figs 1a and 1c). The increase became significant 
for the 65 kDa band at T=4. Next, we performed the same experiment using the frozen half of the temporal 
lobe. Here, we detected N-terminal fragments of the same molecular weight compared with the non-frozen 
tissue, but western blot bands corresponding to full-length and N-terminal htt fragments of more than 100 kDa 
became weaker with increasing artificial PMD (Fig 1b). The relative intensities of the 50kDa and 65kDa 
bands at T=0hr from the frozen sample were higher compared to the non-frozen tissue at T=0hr. This 
difference was 2,06% ±1,38% (p=0.06) for the 50kDa band, and for the 65 kDa band the difference was 
4,63% ± 1,88% (p <0.05). Furthermore, we observed an increase in band intensity in the frozen sample after 
an artificial PMD of 8 hours for N-terminal htt fragments of 50 kDa (10,53% ±5,16%) and 65 kDa (13,33% 
±2,04%) (Fig 1d) compared with T=0, that was already significant after 2 hours. This is in contrast to the 
subtle gradual increase observed in the non-frozen tissue. We did not detect additional N-terminal htt 
fragments that were introduced by the freeze-thaw cycle. This indicates that freezing of brain tissue affects htt 
signal strength, but not the profile of htt protein fragments in control brain tissue samples. 
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Fig 1. N-terminal huntingtin fragments in control temporal lobe tissue. Western blot analysis of temporal lobe 
tissue samples from tissue with no (a) and one freeze-thaw cycle (b) before sampling. Upper blot: full length htt. Middle 
and lower blot: N-terminal htt fragments with β-actin loading control. Squares: position of bands that increase with 
increasing artificial PMD (black = 65kDa, white = 50kDa). kDa = Molecular weight in kilodaltons, Artificial post mortem 
delay in hours (hr). (c) Image J quantification of PMD-related htt bands at indicated timepoints relative to total htt (0 
freeze-thaw cycli). (d) Image J quantification of PMD-related htt bands at indicated timepoints relative to total htt (1 freeze-
thaw cyclus). Columns represent the average of four independent western blots. Black columns: 65 kDa, White columns: 
50 kDa. Error bars indicate standard deviation. * = P<0.05, *** = P<0.001, **** = P<0.0001. 
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Artificial PMD introduces N-terminal htt fragments in HD striatal tissue.  
Using tissue from an HD subject with an initial PMD of 3 hours, we analyzed the effect of an increasing 
artificial PMD in human HD striatal tissue. Western blot analysis of full length htt showed two bands 
corresponding to wild-type and mutant huntingtin which is in agreement with findings in human HD fibroblast 
lysates [29]. Artificial PMD decreased band intensities of full-length htt and most N-terminal htt fragments in 
HD striatal tissue. However, we observed a band at 43 kDa that appeared after an artificial PMD of 24hr (Fig 
2a). Additionally, we were able to detect a band corresponding to a small N-terminal htt fragment (<26 kDa) 
that increased after 24hr, but this low molecular weight band could not reliably be quantified. ImageJ analysis 
of the 43 kDa band (Fig 2b) revealed a significant increase of 11,61% ±3,88% at T=30hr compared with 
T=24hr. 
Fig 2. Effect of artificial post mortem delay on N-terminal huntingtin fragments in post mortem HD 
striatal tissue. (a) Western blot analysis of HD striatal tissue (1 freeze-thaw cyclus). Upper blot: full length htt. Middle 
and lower blot: N-terminal htt fragments with β-actin loading control. Gray square: Band increased with increasing artificial 
PMD. kDa = Molecular weight in kilodaltons, Artificial post mortem delay in hours (hr). (b) Image J quantification of the 
43kDa band at indicated timepoints relative to total htt. Gray columns represent the average of four independent western 
blots. Error bars indicate standard deviation. **=P<0.01.
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Huntington disease subjects show greater variation in full-length and N-terminal huntingtin 
protein fragment profiles.  
Having identified N-terminal htt fragments that can be attributed to longer PMDs, we next analyzed N-
terminal htt fragments in post mortem tissue in nine control subjects (mean age = 61.6 ± 15.5 years, mean 
PMD = 15.8 ± 5.3 hours) and nine HD subjects (mean age = 61.0 ± 17.6 years, mean age = 14.3 ± 2.5 hours). 
For further clinical information see Table 1. We observed that the western blot signal for full-length htt and 
N-terminal htt fragments was stronger in control subjects compared to HD subjects, and overall stronger in
cortical tissue compared to striatal tissue, while no differences in the β-actin loading controls were observed
(S1 Fig). Therefore, for optimal comparison, western blot results for the HD subjects in Figures 3 and 4 are
shown with the odyssey software configured at a higher viewing-sensitivity. In control cortical tissue, results
were similar for subjects C2-C9 showing a consistent banding pattern with subtle interpersonal differences.
The band-pattern for subject C1 was very different, showing relatively more N-terminal htt fragments below
55 kDa (Fig 3a). In HD cortical tissue (Fig 3b), interpersonal variation was more prominent and  subjects
HD1, HD4 and HD5 showed a weaker N-terminal htt profile. Smaller N-terminal htt fragments below 55 kDa
appeared more pronounced with respect to the total htt signal in HD cortical tissue compared with control
cortical tissue (S1 Fig). For both control and HD cortical subjects, western blot bands for N-terminal htt
fragments were most prominent between 43 kDa and 95 kDa. This was in concordance with the N-terminal htt
fragment profile induced by the artificial PMD of > 2 hours in temporal lobe tissue stored at -80°C (Fig 1b).
N-terminal htt fragments of 65kDa and 50kDa that were associated with PMD in temporal lobe tissue were
detected in both control and HD cortical tissue. However, we did not observe a correlation with the PMD’s of
the different subjects.
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Fig 3. Comparison of N-terminal huntingtin fragments in post mortem control and HD cortex. Western 
blot analysis of (a) Control subjects, (b) HD subjects. Control and HD subjects were age, gender and post mortem delay 
matched. Upper blot: full length htt (fl htt). Middle and lower blot: N-terminal htt fragments with β-actin loading control. 
Arrows: position of bands associated with a post mortem delay related increase in intensity in non-HD temporal lobe 
tissue. kDa = Molecular weight in kilodaltons, Post mortem delay in hours (hr). High sensitivity: Blot analyzed at a higher 
viewing-sensitivity. 
Next, we performed western blot on post mortem striatal tissue from the same control and HD subjects (Fig 
4). Between control subjects (Fig 4a) the N-terminal htt fragment profile was similar, but we observed some 
interpersonal variation in signal intensity. The overall htt western blot signal in striatum was weak for all HD 
subjects (Figs 4b and S1). Between HD subjects the N-terminal htt fragment profile was similar with small 
interpersonal variation. Comparison between control and HD subjects for striatum revealed that the most 
prominent N-terminal htt fragment was detected at 80kDa in most control subjects, while in most HD subjects 
(HD1-HD6) the most prominent N-terminal htt fragment was detected at 55kDa. In subjects HD8-HD9, both 
80kDa and 55kDa N-terminal htt fragments were detected equally. For control subjects, N-terminal htt 
fragments of similar sizes can be observed in both cortical and striatal tissue (Figs 3a and 4a). On the other 
hand, in HD subjects the 55kDa N-terminal fragment is less prominent in cortical tissue compared with 
striatum (Figs 3b and 4b). 
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Fig 4. Comparison of N-terminal huntingtin fragments in post mortem control and HD striatum Western 
blot analysis of (a) Control subjects, (b) HD subjects. Control and HD subjects were age, sex and post mortem delay 
matched. Upper blot: full length huntingtin (fl htt). Middle and lower blot: N-terminal htt fragments with β-actin loading 
control. Arrow: position of bands associated with a post mortem delay related increase in intensity in HD striatal tissue. 




In the current study we have examined PMD effects on N-terminal htt protein fragments in human brain tissue 
using western blot analysis on temporal lobe tissue obtained directly post-surgery from a control human 
subject. Our results show that increasing PMD resulted in a gradual increase of N-terminal htt fragment bands 
between 50 kDa-and 65 kDa on western blot. Other studies detected a similar N-terminal htt fragment of 50 
kDa in post mortem human cortical brain tissue obtained from control subjects with a PMD of 9 to 16 hour 
[16, 18]. Within the context of our study, this 50kDa N-terminal htt fragment could be associated with PMD. 
However, other N-terminal htt fragments detected in [16, 18], and the caspase-3 related N-terminal htt 
fragment [11] detected in the cortex of human control subjects were not associated with PMD in our study. 
Our results further indicate that the effect of one freeze-thaw cycle on N-terminal htt fragments is quantitative, 
but not qualitative. We observed that one freeze-thaw cycle reduced the htt signal, especially for larger (>95 
kDa) htt fragments and the full-length protein. Furthermore, PMD-related N-terminal htt fragments at 50kDa 
and 65kDa appeared at earlier time points for tissue that underwent one freeze-thaw cycle, suggesting their 
formation is enhanced due to freeze-thawing. However, no additional N-terminal htt fragments were observed 
due to freeze-thaw effects. Hence, the common practice of tissue storage at -80ºC and subsequent re-thawing 
for use is not expected to greatly influence study results on N-terminal htt fragments. This is an important 
finding because there is a well-established link between HD-pathology and small N-terminal htt fragments [7, 
13]. Our experiments showed that artificial PMD gave rise to different N-terminal htt fragments in post 
mortem control temporal lobe tissue when compared with post mortem HD striatal tissue. This could suggest 
that PMD differently affects HD and control brains or different brain regions, but this difference might also be 
due to interpersonal differences between both subjects. The results on striatal tissue suggest that the 43 kDa 
band that is associated with PMD in HD striatum, appears between 8 and 24 hours. A striatal 43 kDa N-
terminal fragment was reported before in HD striatum with PMD’s of 9 to 16 hours [16]. In our cortical 
control and HD subjects, we observed inter individual differences in N-terminal htt fragments, especially for 
HD subjects. However, we did not observe a correlation between N-terminal htt bands and the PMD’s of 
individual subjects. It is likely that the observed inter individual differences between subjects are mainly 
caused by other factors such as genetic or environmental factors. We did not observe different N-terminal htt 
fragment profiles between control and HD cortical tissue, which is in accordance with previous studies [16, 
18]. However compared with these studies, we detected more larger N-terminal htt fragments. Possibly, this is 
due to the use of different subject-cohorts or western blotting protocols. In our striatal samples, the molecular 
weight of the most prominent N-terminal htt fragment differed between HD and controls. This suggests a 
difference in htt proteolytic cleavage in striatum between controls and HD.  This is in agreement with [16] 
although Mende-Mueller et al reported N-terminal htt fragments of smaller sizes. We were probably not able 
to show these smaller N-terminal htt fragments due to the weak htt western blot signal obtained for HD striatal 
tissue. El-Daher et al, whom utilized the 4C8 antibody also observed weaker htt signals for HD striatum 
compared with controls [31]. On the other hand, studies using an anti N17 antibody did not observe a 
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difference in htt signal between control and HD striatum. [16, 18]. Hence, the observed difference in htt 
western blot signal between control and HD and cortex versus striatum could be due to variability between 
different human post mortem brain tissue specimens.  
Conclusion 
By mimicking PMD and a freeze-thaw cycle separately, we were able to provide an overview of expected 
effects on N-terminal htt fragments in post mortem human brain tissue. According to our results, PMD has a 
mild qualitative influence on N-terminal htt fragments because it introduces new fragments. A freeze-thaw 
cycle has a quantitative effect as it affects huntingtin signal strength. Hence, our study contributes to the 
correct interpretation of data on N-terminal htt fragments obtained from human post mortem brain tissue. 
Furthermore, our results show that subject to subject variation has a larger, both qualitative and quantitative 
effect on N-terminal htt fragments. Hence, our study underscores the need for larger subject cohorts in studies 
involving post mortem human brain tissue. 
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S1 Fig– Levels of N-terminal huntingtin fragments in cortical and striatal tissue.  
All western blots shown at the same sensitivity. (a) Control subjects, Cortical region. (b) HD subjects, Cortical region. (c) 
Control subjects, Striatal region. (d) HD subjects, Striatal region. Control and HD subjects are age, sex and PMD matched. 
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Abstract 
The presence of protein aggregates within the brain is a key hallmark of Huntington disease. To better 
understand regional differences in HD pathology and the link with htt aggregation, it is important to 
quantify htt aggregates in different brain regions. In this small-scale pilot study we have assessed the 
correlation between the presence of insoluble htt protein as determined by the filter-trap assay, and 
counted aggregates in brain tissue sections. Our results indicate that the filter-trap assay is a promising 
technique to quantify protein aggregates in post-mortem human brain tissue. 
Introduction 
Huntington disease (HD) is an autosomal dominant neurodegenerative disease [1] caused by 
elongation of an exonic CAG-repeat within the HTT gene [2]. This mutation results in a mutant 
huntingtin protein (mutHtt) with an expanded polyglutamine repeat (polyQ) [3] that is prone to 
aggregation [4]. The presence of mutHtt protein aggregates is a key hallmark of HD [2, 5]. However, 
the link between mutHtt aggregates and HD pathology is elusive. A pathological role of mutHtt 
aggregates in HD has been suggested in some studies [6, 7]. However other studies suggests that 
mutHtt aggregate formation is beneficial for cells [8, 9], which indicates that soluble mutHtt is more 
toxic. The quantification of mutHtt aggregates in HD brain tissue should aid to further elucidate their 
role in HD pathogenesis. Quantification of protein aggregates can be performed by counting 
aggregates in tissue sections using a microscope, which is a cumbersome procedure. The filter-trap 
assay is a simple assay used to objectively quantify mutHtt aggregates [10] and has been used with 
PC12 cell lysates [11], and brain homogenates of R6/2 mice [12]. In this pilot study, we have used the 
filter-trap assay to quantify mutHtt aggregation in post-mortem human brain tissue. Our results 
indicate that there could be a correlation between the filter-trap assay and the number of aggregates as 
counted in tissue-sections. Furthermore, we found more mutHtt aggregates in cortical tissue compared 
with striatal tissue in one juvenile Huntington disease case which is in concordance with the 
immunohistochemistry results from [8]. Our results suggest that the filter-trap assay can be used to 
quantify mutHtt aggregates in post-mortem human brain tissue.  
Materials and Methods 
Post-mortem human brain tissue lysates. 
Post-mortem human cortical and striatal brain tissue from control and HD subjects was obtained from 
the Neurological Foundation of New Zealand Human Brain Bank, Centre for Brain Research, 
University of Auckland and the department of pathology, Leiden University Medical Centre. Tissue 
was obtained with the approval of the institutes ethics committee and informed consent. Clinical 
information in table 1. 
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Table 1. Clinical information of subjects 
Type Subject Grade Gender PMD CAG Age A.o.O.
Control H121 n.a. F 6 18 : 23 64 n.a.
HD HC105 1 F 9 15 : 42 67 47 
HD HD166 2 M 32 17 : 42 80 >70
HD HD193 3 M 18 9 : 44 68 44 
HD HC90 3 M NA 23 : 41 61 51 
HD HC140 3 M 22 17 : 40 62 44 
HD HC125 3 F 13 17 : 43 67 45 
HD HC139 3 F 5 14 : 41 67 15 
jHD HC104 3 M 15 18 : 53 40 15 
jHD HD29 NA F 11 20 : 84 11 8 
jHD HD86 3 F 20 17 : 84 20 16 
jHD HD192 NA M NA 17 : 51 37 NA 
jHD HD208 NA M NA 15 : 68 37 ~ 23 
 
HD = Huntington disease, jHD = Juvenile Huntington disease, F=Female, M=Male, PMD = Post-mortem delay, 
A.o.O. = Age of onset, n.a. = not applicable. NA = not assessed.HD = subject with a mutant CAG repeat between
35 and 50. jHD = subject with a mutant CAG repeat of 50 or more.
Immunohistochemistry 
Slide preparation: Tissue sections (thickness 8µm) were formalin fixed and embedded in paraffin. 
After paraffin removal, tissue sections were rehydrated and washed with PBS + Triton X-100. 
Sections were incubated in 50% methanol. Primary antibody (rabbit anti huntingtin): 3702-1 
(Epitomics, Burlinggame CA, USA), or mouse anti htt EM48 (Millipore, Billerica MA, USA). 
Primary antibodies were diluted 1:500. Negative control: sections not incubated with a primary 
antibody. Secondary antibody: goat anti-rabbit or goat anti-mouse (Santa Cruz, Dallas TX, USA) 
diluted 1:1000. Streptavidin/DAB: Tissue sections were incubated with Streptavidin-HRP (diluted 
1:2000 in 1% normal goat serum), followed by 10 minutes of incubation in DAB solution. Sections 
were Nissl-counterstained and examined for aggregates by microscope. Qualitative determination of 
aggregate abundance: Total number of aggregates for any combination of HD (adult-onset/juvenile), 
antibody (EM48/3702-1) and brain region (cortex/striatum) was subtracted by the number of 
aggregates counted in the corresponding negative control. The resulting number determines the 
qualitative abundance of aggregates where “+” = 1-5, “++” = 6-10, “+++” = 11-15, “++++” = > 15. 
Preparation of insoluble protein fractions 
Homogenization of human brain tissue sections:  bullet blender (Next Advance, str 8, 3 min). 
Homogenization buffer: 150mM Sucrose, 15mM HEPES pH7.9, 60mM KCl, 0.5mM EDTA pH8 and 
0.1mM EGTA pH8 (W/V ratio: 1:5). Added Triton X-100 (final concentration 1%). Stored on ice (1 
hour). Preparation of pellet fraction: Homogenized tissue was centrifuged (14000rpm/10min) 
followed by 3x wash in wash-buffer (60mM Tris) subsequently followed by pellet-resuspension in 
15% SDS and an o.n. incubation at 95ºC. The bicinchoninic (BCA) assay kit (Thermo Fisher 
Scientific,Waltham, USA) was used to determine protein concentration. 
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Filter-trap assay 
Dot-blot: 100µg of pellet fraction in 300 µl of 15% SDS was applied onto a cellulose acetate 
membrane (Schleicher & Schuell,St Louis, USA, 0.2µm pore-size) with the Bio-Rad Bio-Dot 
apparatus (Bio-Rad, #1706545). Wash: 2x in 0.2% SDS. Fixation: 0.5% glutaraldehyde (20 min). 
Blocking of blot membranes was performed with 4% non-fat milk (Nutricia, Schiphol, The 
Netherlands) in TBST. Primary antibody (rabbit anti huntingtin): 3702-1, diluted 1:5000 
(Epitomics). Secondary antibody: HRP conjugated goat anti rabbit, diluted 1:10000 (Santa 
Cruz). Visualization of results: ECL (#32106, ThermoFisher) and Hyperfilm ECL (#28906837, GE 
healthcare, Little Chalfond, United Kingdom). Quantification of signal intensity was performed with 
ImageJ-software. Results represent the average of three independent filter-trap assays. 
Results 
Immunohistochemistry reveals more huntingtin aggregates in juvenile HD compared with 
adult-onset HD tissue sections. 
Immunohistochemistry was performed on four adult-onset HD subjects (HC90, HC125, HC139 and 
HC140, average age = 64.3y ±3.2y, average mutant CAG = 41.3 ± 1.3), and four juvenile HD subjects 
(HD86, HC104, HC192 and HD208, average age = 33.5y ±9.1y, average mutant CAG = 64.0 ± 15.3). 
In Table 1, a qualitative overview of the amount of aggregates in adult-onset HD or juvenile HD 
cases is shown. On average, htt aggregates were more abundant in the juvenile HD tissue sections. 
Table 1 – Qualitative determination of aggregates in HD subjects 
Immunohistochemistry was performed with either EM48 or 3702-1 as primary antibody. 
Note: juvenile HD is defined here as any case with a CAG repeat of 50 or longer.  
Insoluble huntingtin protein levels in Huntington disease subjects 
For the filter-trap assay, we first used cortical brain tissue lysates from five HD subjects with 
increasing polyQ-repeats, and one non-HD subject as a negative control (Figure 1). As expected, the 
negative control (H121) did not produce a significant signal indicating no insoluble huntingtin protein 
is present. Filter-trap analysis on the five HD subjects showed that the average signal-intensity per 
subject, as measured from three independent filter-trap assays, showed increased intensity of the filter 
trap assay dots with larger polyQ-repeats (Figure 1). This was in agreement with the qualitative 
determination of aggregates in HD subjects shown in table 1. 
Adult-Onset HD Cortex Striatum Juvenile HD Cortex Striatum 
EM48 + + EM48 +++ +++ 
3702-1 + + 3702-1 ++++ +++ 
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Figure 1 - Insoluble htt proteins in human adult-onset and juvenile HD brain tissue. 
Left Filter-trap assay of SDS-insoluble htt protein in cortical human brain tissue of one control subject (H121), 
three adult-onset HD subjects (HC105, HD166, HD193) and two juvenile HD subjects (HC104, HD29). PolyQ-
lengths shown next to dots. 100µg of protein was loaded per dot. Blots were probed with an anti htt antibody. Dot 
intensity indicates level of insoluble htt protein. Right Comparison of dot intensities per subject as determined 
with imageJ analysis. Black bars represent the average dot intensity from three independent dot blot assays. 
Standard deviation indicated by error bars. 
Insoluble huntingtin protein in subject HD86 Cortex and Striatum 
From one juvenile HD case we independently analyzed brain tissue lysates originating from the 
striatum and cortex using the filter-trap assay (Figure 2). For this subject, our results clearly show a 
significant difference, with more insoluble huntingtin present in the cortical sample (Figure 2). 
Figure 2 - Insoluble htt protein in cortex and striatum of juvenile HD subject HD86. Left Filter-trap 
assay of SDS-insoluble htt protein in cortical and striatal human brain tissue of one juvenile HD case. 100µg of 
protein was loaded per dot. Blots were probed with an anti htt antibody. Dot intensity indicates level of insoluble 
htt protein.  Right Comparison of dot intensities per area as determined with imageJ analysis. Bars represent 
average dot intensity from three independent assays. Standard deviation indicated by error bars. * = P<0.05.
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Discussion 
The results of our pilot-study are encouraging for the use of the filter-trap assay in the quantification 
of protein aggregates in post-mortem human HD brain tissue. No discernible signal was obtained with 
the non-HD control subject which indicates that, despite the use of  human brain material and the 
rigorous procedure to suspend the protein pellet, background is not an issue. We observed that the 
signal intensity for insoluble htt protein showed an increase with increasing polyQ repeats. One 
possible explanation is that increased polyQ repeats are more prone to aggregate formation [13]. The 
current study, does not elucidate whether the increased signal is due to more efficient aggregation of 
larger polyQ-repeats, or is merely mirroring differences in protein expression levels. In an earlier 
study, we have looked at soluble wild-type and mutant huntingtin protein levels in post-mortem 
human HD brain tissue [14]. Results from that study indicate that soluble mutant huntingtin protein 
levels were lower for juvenile HD cases. This suggests an inverse correlation between levels of 
aggregated and soluble mutant huntingtin, which is in accordance with results obtained by Baldo et al 
[12]. In addition, we demonstrated the filter-trap assay’s ability to assess differences in the level of 
insoluble htt protein within different brain regions. The difference in insoluble huntingtin protein 
levels we found in our juvenile HD subject HD86 are in concordance with the results by Gutekunst et 
al [8] who found that huntingtin aggregation was predominantly present within the cortex. In 
conclusion, the data from this pilot-study provide a proof-of-principle of the filter trap assay to be 
used as a quantitative assay for determining the level of huntingtin protein aggregation in post-mortem 
human brain tissue. 
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DOI 10.1186/s13024-015-0018-7RESEARCH ARTICLE Open AccessMaking (anti-) sense out of huntingtin levels in
Huntington disease
Melvin M Evers1†, Menno H Schut1†, Barry A Pepers1, Melek Atalar2, Martine J van Belzen3, Richard LM Faull4,
Raymund AC Roos5 and Willeke MC van Roon-Mom1*Abstract
Background: Huntington disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by
motor, psychiatric and cognitive symptoms. HD is caused by a CAG repeat expansion in the first exon of the HTT
gene, resulting in an expanded polyglutamine tract at the N-terminus of the huntingtin protein. Typical disease
onset is around mid-life (adult-onset HD) whereas onset below 21 years is classified as juvenile HD. While much
research has been done on the underlying HD disease mechanisms, little is known about regulation and expression
levels of huntingtin RNA and protein.
Results: In this study we used 15 human post-mortem HD brain samples to investigate the expression of wild-type
and mutant huntingtin mRNA and protein. In adult-onset HD brain samples, there was a small but significantly lower
expression of mutant huntingtin mRNA compared to wild-type huntingtin mRNA, while wild-type and mutant
huntingtin protein expression levels did not differ significantly. Juvenile HD subjects did show a lower expression of
mutant huntingtin protein compared to wild-type huntingtin protein. Our results in HD brain and fibroblasts suggest
that protein aggregation does not affect levels of huntingtin RNA and protein. Additionally, we did not find any
evidence for a reduced expression of huntingtin antisense in fibroblasts derived from a homozygous HD patient.
Conclusions: We found small differences in allelic huntingtin mRNA levels in adult-onset HD brain, with significantly
lower mutant huntingtin mRNA levels. Wild-type and mutant huntingtin protein were not significantly different in
adult-onset HD brain samples. Conversely, in juvenile HD brain samples mutant huntingtin protein levels were lower
compared with wild-type huntingtin, showing subtle differences between juvenile HD and adult-onset HD. Since most
HD model systems harbor juvenile repeat expansions, our results suggest caution with the interpretation of huntingtin
mRNA and protein studies using HD cell and animal models with such long repeats. Furthermore, our huntingtin
antisense results in homozygous HD cells do not support reduced huntingtin antisense expression due to an expanded
CAG repeat.
Keywords: Huntington disease, Huntingtin, Huntingtin antisense transcript, Post-mortem HD brain tissue,
HD patient-derived fibroblasts, Juvenile HDBackground
Huntington disease (HD) is an autosomal dominant neu-
rodegenerative disorder, characterized by motor, psychi-
atric and cognitive symptoms [1]. HD is caused by a
CAG repeat expansion in the first exon of the HTT gene
on chromosome 4p16, resulting in an expanded polyglu-
tamine (polyQ) tract at the N-terminus of the huntingtin* Correspondence: w.vanroon@lumc.nl
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unless otherwise stated.(htt) protein. People carrying 40 or more CAG repeats
will develop HD, whereas people with 36 to 39 repeats
show reduced penetrance [2,3]. The mean disease onset
lies between 30 and 50 years of age (adult-onset HD).
HD patients carrying more than 50 CAGs will have a
disease onset typically below 21 years of age (juvenile
HD) [1]. The major neuropathology in HD occurs in the
striatum and cerebral cortex but degeneration is seen
throughout the brain as the disease progresses [4] and
insoluble protein aggregates in the nucleus and cyto-
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expression is limited and inconsistent. In patient-derived
lymphoblasts, no CAG repeat-related effect on total
HTT mRNA was observed [6], suggesting that there is
no difference in wild-type and mutant HTT RNA ex-
pression. On the other hand, upregulation of mutant
HTT mRNA translation in HD was suggested by inter-
action of the expanded CAG repeat with the MID1-
PP2A complex [7]. Upregulation of mutant HTT mRNA
translation was also suggested by HTT antisense tran-
script regulation [8]. Two natural HTT antisense tran-
scripts (HTTAS) were identified at the HTT locus, of
which one HTTAS contains a CTG repeat. Overexpres-
sion of HTTAS resulted in reduced HTT transcript
levels, whereas knockdown increased HTT transcript
levels [8]. Furthermore, in post-mortem HD brain no
HTTAS with an expanded CTG repeat could be de-
tected. From these observations, it was suggested that
HTTAS negatively regulated HTT transcript expression
and that loss of HTTAS in HD increases mutant HTT
mRNA levels [8]. Upregulation of mutant HTT mRNA
in human post-mortem HD brain tissue was confirmed
recently using an allele-specific quantitative (q)PCR [9].
However, endogenous mRNA expression levels have not
been related to subsequent mutant and wild-type htt
protein levels. Also the effect of the presence of insol-
uble protein aggregates on htt protein levels is not
known.
In this study we have examined HTT mRNA and htt
protein levels in HD patient-derived fibroblasts and
post-mortem brain tissue with varying CAG repeat
lengths. We find a decrease in mutant HTT mRNA
levels compared to wild-type in adult-onset HD patients.
However, this reduced mutant HTT mRNA expression
did not result in lower mutant htt protein levels. In con-
trast, juvenile HD fibroblasts and brain tissue did show
lower levels of mutant htt protein compared to wild-
type htt protein, indicating subtle differences in htt pro-
tein expression between adult-onset and juvenile HD.
Results
Validation of RT-PCR amplification across the CAG repeat
To reliably measure both wild-type and mutant HTT
mRNA we first optimized our PCR procedure to account
for differences in amplification across the CAG repeat
expansion. To exclude amplification bias across the
CAG repeat in our PCR [10], we fitted a linear regres-
sion curve of both wild-type and mutant HTT genomic
DNA (gDNA) with increasing PCR cycles (Figure 1A).
PCR linearity was evaluated by determining the linear
regression coefficient (r2) of the band intensities versus
the number of PCR cycles. Both wild-type and mutant
PCR products showed a linear increase in gel electro-
phoresis band intensity with increasing PCR cyclenumber (wild-type, r2 = 0.8680; mutant, r2 = 0.8282). The
slopes were not significantly different (P = 0.6485), indi-
cating that the PCR was equally efficient for both wild-
type and mutant HTT. Additionally, we always used
gDNA as a reference since gDNA has a 1:1 ratio of nor-
mal and expanded HTT. Next, we performed RT-PCR
expansion across the CAG repeat using four adult-onset
HD patient-derived fibroblasts (Figure 1B). Reverse tran-
scription without reverse transcription enzyme was
taken along, verifying that there was no gDNA contam-
ination in our RT-PCR (Figure 1C). For each fibroblast
line the two PCR products corresponding to wild-type
and mutant HTT mRNA were quantified and average
expression levels of wild-type and mutant HTT mRNA cal-
culated (Figure 1D). No significant difference (P = 0.7642)
between wild-type and mutant HTT mRNA expression
was observed in adult-onset HD patient-derived fibroblasts.
Less mutant HTT mRNA in human post-mortem HD brain
material
Next, we investigated HTT mRNA expression levels in
post-mortem brain tissue from HD patients with a wide
range of repeat lengths. RNA and gDNA was isolated from
frontal cortex or middle temporal gyrus and PCR was per-
formed with primers flanking the CAG repeat (Figure 2A).
The wild-type and mutant PCR products for each brain
sample were quantified and normalized against PCR prod-
ucts from gDNA and individual wild-type versus mutant
HTT mRNA expression levels were calculated. Next, the
average expression levels of wild-type and mutant HTT
mRNA in the frontal cortex (Figure 2B) and middle tem-
poral gyrus (Figure 2C) of adult-onset HD patients were
calculated. We found a significant 31.0% (SEM± 6.1%)
lower average mutant HTT mRNA compared to wild-type
HTT mRNA expression in the frontal cortex from HD
patients. In the middle temporal gyrus, a 22.1% (SEM±
10.9%) lower average mutant HTT mRNA expression was
found. When we combined all the brain samples and
repeated the analysis we found a significant lower average
mutant HTT mRNA expression of 26.6% (SEM± 6.1%)
compared to wild-type HTT mRNA (Figure 3A).
To validate our results with a different technique, we
performed a single nucleotide polymorphism (SNP)-spe-
cific TaqMan qPCR, using probes for rs362273 SNP
located at on the 3′ side of HTT in exon 57. Of our
post-mortem brain samples, 6 out of 14 were heterozy-
gous for rs362273. Next, SNP linkage by circularization
(SLiC) [11] was performed to determine which allele has
the guanine and which allele the adenine in exon 57.
Due to the variable RNA quality of brain tissue, SLiC
was only possible in 4 out of 6 samples. TaqMan qPCR
showed an identical trend towards more wild-type HTT
as was found for our RT-PCR analysis (Figure 3B), but
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Figure 1 Validating RT-PCR amplification across the CAG repeat in HD patient-derived fibroblasts. Wild-type and mutant HTT were separated by
gel electrophoresis. (A) Standard curve of wild-type and mutant HTT RT-PCR products with increasing PCR cycles from gDNA derived from
post-mortem brain tissue of 7 HD patients. PCR linearity was evaluated by determining the individual linear regression coefficients (r2) of the band
intensities of wild-type and mutant HTT expression versus the number of PCR cycles, n = 7. (B) PCR products from cDNA of 4 HD (GM00305,
GM02173, GM04022, GM04855) fibroblasts. CAG repeat sizes for the wild-type (lower band) and mutant alleles (upper band) are indicated below
each lane. gDNA was used to examine differences in PCR amplification between the wild-type and mutant product due to the CAG repeat
expansion. (C) RT-PCR products with input: cDNA (+RT), cDNA lacking reverse transcriptase (−RT) and gDNA of one control (GM04204). (D) Whisker
boxplot of RT-PCR from HD patient-derived fibroblasts, comparing wild-type and mutant HTT mRNA expression levels, relative to gDNA. Line =mean,
pair wise differences were evaluated using linear mixed model, n = 4.
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fication across the CAG repeat is an accurate technique to
measure small allelic differences in mRNA expression.
Despite a lower RNA quality in our juvenile HD sam-
ples compared to the adult-onset HD samples, we were
able to separate both alleles by amplification across the
CAG repeat in cDNA and gDNA samples (Figure 4A).
Consistent with adult-onset HD samples, we found a
22.6% (SEM± 10.6%) lower mutant HTT mRNA expres-
sion compared to wild-type HTT mRNA in post-mortem
brain tissue from juvenile HD patients (Figure 4B).
No difference in wild-type and mutant htt protein levels
in adult-onset HD
To relate the observed differences in allelic HTT mRNA
expression to wild-type and mutant htt protein levels,
we analyzed SDS-soluble htt protein levels in both HD
fibroblasts (Figure 5A) and post-mortem human HD
brain homogenates (Figure 5B) using Western blot.
Wild-type and mutant htt protein bands were quantified
and both the individual wild-type and mutant htt protein
levels were calculated as well as the average of all indi-
vidual measurements. No significant difference betweenwild-type and mutant htt protein levels in patient-
derived fibroblasts was found (Figure 5C). Likewise, in
the post-mortem human HD brain homogenates there
was no difference in wild-type and mutant htt protein
levels (Figure 5D).
It is known that in post-mortem human HD brain,
mutant htt aggregates in a polyQ length-dependent
manner [12], while no mutant htt aggregates are present
in HD patient-derived fibroblasts [13]. Our results show
that the levels of soluble wild-type and mutant htt pro-
tein do not change in the absence or presence of htt
protein aggregates.
Less mutant than wild-type htt protein in juvenile HD
Next, we analyzed SDS-soluble wild-type and mutant htt
levels in juvenile HD samples. Htt protein levels from
patient-derived fibroblasts with mutant polyQ lengths of
73, 99 and 181 were analyzed onWestern blot (Figure 6A).
Juvenile HD fibroblast lysates showed a significant 10.1%
(SEM± 2.7%) lower level of mutant htt protein compared
to wild-type htt (Figure 6B).
Next, we analyzed SDS-soluble levels of wild-type and






































































































































Figure 2 Wild-type and mutant HTT mRNA levels in adult-onset HD brain tissue. Wild-type and mutant HTT mRNA PCR products were separated
on gel electrophoresis by differences in their CAG repeat length. (A) RT-PCR products from brain tissue derived from a control (H121) and 10 HD
patients. Allelic CAG repeat sizes are indicated below each lane. gDNA from each sample was taken along to control for differences in PCR
amplification efficiencies across the CAG repeat. (B) Whisker boxplot of allelic HTT mRNA expression levels in frontal cortex from 5 HD adult-onset
HD patients. (C) Whisker boxplot of allelic HTT mRNA expression levels in middle temporal gyrus from 5 HD adult-onset HD patients. Expression
levels relative to gDNA. Pair wise differences were evaluated using linear mixed model, n = 5.
Evers et al. Molecular Neurodegeneration  (2015) 10:21 Page 4 of 11lysates. Three of the four juvenile HD brain lysates showed
multiple mutant htt protein products (Figure 6C). Despite
of the reduced quality of the post-mortem juvenile HD
brain lysates, we were able to quantify the protein bands
and showed 16.4% (SEM± 7.0%) lower mutant htt protein
levels with respect to wild-type htt (Figure 6D).
These results show that in adult-onset HD samples, wild-
type and mutant htt protein levels are equal, regardless ofA RT-PCR
































Figure 3 HTT mRNA quantification after RT-PCR amplification across the CAG
of wild-type versus mutant HTT mRNA expression levels in adult-onset HD po
CAG repeat, relative to gDNA. Pair wise differences were evaluated using linea
normalized to β-actin (ACTB). Data were evaluated using a two-tailed studentmutant htt protein aggregation. In juvenile HD there is a
consistent lower level of mutant htt protein expression.
HTT antisense expression in HD patient-derived fibroblasts
and post-mortem brain tissue
It is known that a lower expression of HTTAS that contains
the CTG repeat can increase HTT mRNA expression [8].


































repeat compared to SNP-specific quantitative RT-PCR. Whisker boxplots
st-mortem brain material. (A) Quantification after amplification across the
r mixed model, n = 10. (B) SNP rs362273-specific quantitative RT-PCR,


























































Figure 4 Wild-type and mutant HTT mRNA levels in juvenile HD brain. Wild-type and mutant HTT mRNA PCR products were separated by gel
electrophoresis. (A) RT-PCR products from brain tissue derived from two juvenile HD patients (HD192 and HC104). CAG repeat sizes for the
wild-type and mutant alleles are indicated below each lane. gDNA was used to control for differences in PCR amplification between the
wild-type and mutant product due to the CAG repeat expansion. (B) Whisker box plot comparing wild-type and mutant HTT mRNA expression
levels, relative to gDNA. Pair wise differences were evaluated using linear mixed model, n = 4.
Evers et al. Molecular Neurodegeneration  (2015) 10:21 Page 5 of 11observed were due to higher HTTAS expression we investi-
gated HTTAS expression in fibroblasts and post-mortem
brain tissue from HD patients. In post-mortem brain tissue
we detected comparable levels of HTTAS in HD and con-
trol brain tissue (Figure 7A). We could also reliably detect
HTTAS in all cell lines that we investigated, including the
homozygous HD patient-derived fibroblasts (Figure 7B).
Sanger sequencing confirmed that this was HTTAS with
the expanded CTG repeat. This was unexpected since re-
duced expression of HTTAS with an expanded CTG repeat
was reported in post-mortem HD brain [8], which would
suggest no expression of this HTTAS when both HTT
alleles contain an expanded repeat. We conclude that our
























































Figure 5 Wild-type and mutant htt protein levels in HD fibroblasts and bra
fibroblasts from three HD patients (GM02173, GM04022, GM04855). The low
repeat lengths are indicated below each lane. (B) Western blot analysis of
comparing wild-type and mutant htt levels normalized against total htt in
wise differences were evaluated using linear mixed model.levels in post-mortem brain are probably not caused by
altered transcription of HTTAS with an expanded CTG
repeat.
Discussion
In the current study we found that in post-mortem
adult-onset HD brain material the levels of wild-type
and mutant HTT mRNA were significantly different. We
found lower levels of mutant HTT mRNA compared to
wild-type in the frontal cortex and a trend towards lower
mutant HTT mRNA levels in the middle temporal gyrus.
In adult-onset HD patient-derived fibroblasts the levels
of wild-type and mutant HTT mRNA did not differ.

























































in tissue. (A) Western blot analysis of total protein lysates from human
er band represents wild-type htt, the upper band mutant htt. PolyQ
cortical brain homogenates from six HD subjects. (C) Whisker box plots
HD fibroblasts (n = 3) and (D) post-mortem brain tissue (n = 6). Pair
84
juvenile HD brains

































































































Figure 6 Wild-type and mutant htt protein levels in juvenile HD fibroblasts and brain tissue. (A) Western blot analysis of total protein lysates
from human fibroblasts derived from three juvenile HD subjects (GM04281, GM05539, GM09197). The lower band represents wild-type htt, the
upper band mutant htt. PolyQ repeat lengths are indicated below each lane. (B) Whisker box plot comparing wild-type and mutant htt levels
normalized against total htt in juvenile HD fibroblasts (n = 3). (C) Post-mortem cortical brain tissue from four juvenile HD subjects (HD192, HC104,
HD86, HD29). (D) Whisker box plot comparing wild-type and mutant htt levels normalized against total htt in juvenile HD post-mortem brain
tissue (n = 4). Pair wise differences were evaluated using linear mixed model.
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expanded CAG repeat did not affect HTT mRNA
expression [6]. Conversely, a small (~10%) upregulation
of mutant HTT mRNA was recently shown in human
post-mortem HD brain tissue using SNP-specific qPCR
[9]. These contradictory results could be explained by
the fact that the two SNP’s used in this study were both
located outside HTT Exon 1 (3′UTR, and Exon 50). Fur-
thermore, the small upregulation of mutant HTT mRNA
was most pronounced in post-mortem brain material de-
rived from patients with early neuropathological grades
(grades 1 and 2), whereas the material in our study was
generally of later disease stages (grades 3 and 4).
Wild-type and mutant htt protein levels did not signifi-
cantly differ in either fibroblasts or post-mortem brain sam-
ples of adult-onset HD patients. Soluble htt has a half-life
of approximately 24 hours [14] and we hypothesize that
with Western blot analysis we detect soluble htt that is
present in the cells. Protein aggregation is an important
feature in HD brain tissue, but does not occur in HD fibro-
blasts [13], our results show that protein aggregation does
not affect the levels of soluble htt protein. However, we did
find lower mutant HTT mRNA levels in brain. A possible
explanation could be an enhanced translation of mutant
HTT mRNA, resulting in equal htt protein levels. Recently,
increased translation of mutant HTT was suggested [7].Cells overexpressing N-terminal htt fragments with a nor-
mal and mutant polyQ repeat showed an enhanced protein
synthesis of htt fragments with an expanded polyQ repeat.
This more efficient translation of mutant HTT mRNA was
proposed to be caused by enhanced binding of the MID1-
complex to the expanded CAG repeat and mediated by
mTOR and S6K kinases [7].
Two of the three juvenile HD brain lysates showed
multiple mutant htt protein products. This could be due
to somatic mosaicism of mutant htt in the brain of
juvenile patients [15] or due to reduced protein quality
caused by the post-mortem delay. These multiple mu-
tant htt protein products were not present in the fibro-
blast samples. Nonetheless, we consistently, found that
the levels of mutant htt protein were lower than wild-
type in both fibroblasts and post-mortem brain tissue of
juvenile HD patients. This is in contradiction with previ-
ous studies in knock-in HD mice carrying one or two al-
leles with 111 CAG repeats [7], which showed increased
mutant htt protein levels. The lower mutant htt protein
level in juvenile HD is consistent with lower levels of
mutant HTT mRNA. Although juvenile HD is much
rarer than adult-onset HD [16], for development of a
rapid phenotype HD animal models generally carry a
mutant HTT transgene with juvenile CAG repeats [17].

























































Figure 7 HTT antisense expression in HD patient-derived fibroblasts and
brain tissue. Gel electrophoresis of HTTAS amplified using strand- and
HTTAS isoform-specific primers. (A) RT-PCR of patient-derived fibroblasts
from a control (GM04204), an HD patient (GM02173), an HD patient
homozygous for the CAG repeat expansion (GM04857) and a juvenile
HD patient (GM05539). (B) RT-PCR of post-mortem brain tissue from a
control (H121), an HD patient (HC105), and 2 juvenile HD patients
(HD192 and HD86). Allelic CAG repeat sizes below each lane.
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brain samples and this should be taken into account when
interpreting results from HD models carrying a juvenile
repeat expansion.
Recently it has been suggested that in polyQ disorders
bidirectional RNA transcription could play a role in the
disease pathology by deregulation of the sense transcript
[8,18]. It was hypothesized that a bidirectional RNA tran-
script called HTTAS, negatively regulates htt transcript
expression [8]. In accordance, in HD patient-derived fibro-
blasts and brains HTTAS with the expanded CTG repeat
could not be detected [8]. Our results show HTTAS
expression in all HD samples and most notably in patient-
derived fibroblasts homozygous for the CAG repeat
expansion, suggesting that there is an HTTAS with ex-
panded CTG repeat transcribed. We can conclude how-
ever that differences in allelic HTT transcript levels in
post-mortem brain are probably not caused by lower levels
of HTTAS.Recent advances have shown the potential of reducing
mutant htt levels with oligonucleotide-based therapeutics.
Reduction of both wild-type and mutant htt up to 70% was
well tolerated in HD rodent models and non-human pri-
mates [19]. Long-term suppression of wild-type and mutant
htt might not be desirable because of htt’s anti-apoptotic
function [20] and importance for cell survival in the adult
brain [21,22]. A different approach would be an allele-
specific reduction of mutant htt. This could be achieved
with oligonucleotides directed against SNPs unique to the
mutant htt transcript, or by targeting the expanded CAG
repeat directly [23]. Although our allelic HTT mRNA ex-
pression levels are in disagreement to that of Liu et al. [9],
the overall differences in basal HTT mRNA in both studies
are small. This shows that the levels of wild-type and mu-
tant htt protein are not considerably different and provides
feasibility for oligonucleotide therapeutics that are not com-
pletely specific for the mutant HTT allele.Conclusions
Although we found significantly lower mutant HTT
mRNA levels in adult-onset HD, wild-type and mutant htt
protein levels did not differ significantly in adult-onset HD
brain samples. Conversely, in juvenile HD brain samples
mutant htt protein levels were lower compared with wild-
type htt, showing subtle differences between juvenile HD
and adult-onset HD. Since most HD model systems har-
bor juvenile repeat expansions, our results suggest caution
with the interpretation of htt mRNA and protein studies
using HD cell and animal models with such long repeats.
Furthermore, our HTTAS results in homozygous HD cells
do not support reduced HTTAS expression due to an
expanded CAG repeat.Methods
Patient-derived fibroblasts and human brain samples
Fibroblasts derived from HD patients and controls
were purchased from Coriell Cell Repositories, Camden,
USA (Table 1). Fibroblasts were cultured at 37°C and 5%
CO2 in Minimal Essential Medium (Gibco Invitrogen,
Carlsbad, USA) with 15% heat inactivated Fetal Bovine
Serum (Clontech, Palo Alto USA), 1% Glutamax (Gibco)
and 100 U/ml penicillin/streptomycin (Gibco).
Post-mortem human brain tissue was obtained from
the Neurological Foundation of New Zealand Human
Brain Bank in the Centre for Brain Research, University
of Auckland, and the brain bank from the department of
Neurology, Leiden University Medical Center. Tissue
was obtained with the families full consent and with the
ethical approval of the various institutional Ethics Com-
mittees. For a complete list of samples and correspond-
ing clinical information, see Table 2.86
Table 1 Patient-derived fibroblasts
Name CAG 1 CAG 2 Type Age at sampling Age of onset Sex
GM00305 42 15 HD 56 46 F
GM02173 44 17 HD 52 NA F
GM04022 44 18 HD 28 NA F
GM04855 48 20 HD 11 26 M
GM04857 50 40 Homozygous HD 23 28 F
GM04281 71 17 Juvenile HD 20 14 F
GM05539 97 22 Juvenile HD 10 2 M
GM09197 179 18 Juvenile HD 6 NA M
GM04204 18 17 Control 81 NA M
M: male, F: female, NA: not assessed.
Samples ranked on CAG repeat size of the longest allele.
Evers et al. Molecular Neurodegeneration  (2015) 10:21 Page 8 of 11CAG repeat sizing
Genomic DNA samples were isolated from patient-
derived fibroblasts and human brain using the Wizard
Genomic DNA Purification Kit (Promega, Madison,
USA) according to manufacturer’s instructions and
diluted to 50 μg/ml. The number of CAG repeats in
the HTT gene was determined by PCR using primers
“HD-1” and “HD-3” as described previously [24],
followed by fragment analysis on an ABI 3130 Auto-
mated Capillary DNA Sequencer (Applied Biosystems,
Life Technologies Corporation, Carlsbad, USA). The
exact PCR conditions are available on request. The 3′
CAA and following CAG are not counted. For the
polyQ repeat the CAA and CAG triplet are counted
and the polyQ repeat is therefore 2 units longer than
the CAG repeat size.Table 2 Post-mortem human brain tissue
Name CAG 1 CAG 2 Type Tissue P
HC103 40 19 HD MTG 1
HC105 42 15 HD MTG 9
HD166 42 17 HD FC 3
HC102 43 17 HD MTG 1
HC107 43 19 HD MTG 3
HD193 44 9 HD FC 1
HD188 44 16 HD FC N
HD195 44 22 HD FC 8
HD159 47 17 HD FC 4
HC114 47 21 HD MTG 1
HD192 52 18 Juvenile HD FC 6
HC104 53 18 Juvenile HD MTG 1
HD86 84 17 Juvenile HD FC 2
HD29 84 20 Juvenile HD FC 1
H121 23 18 Control MTG 6
MTG: middle temporal gyrus, FC: frontal cortex, PMD: post-mortem delay (hours), G
Samples ranked on CAG repeat size of the longest allele.RNA and genomic DNA analysis
Post-mortem brain tissue was homogenized using cer-
amic MagNA Lyser beads (Roche, Mannheim, Germany)
by grinding in a Bullet Blender (Next Advance, Averill
Park, USA) according to manufacturer’s instructions.
Total RNA was isolated from fibroblast cells and brain
tissue using the Aurum Total RNA Mini Kit (BioRad,
Hercules, USA), with an on-column DNase treatment
for 30 min. RNA was eluted in 40 μl elution buffer and
cDNA was synthesized from 1 μg total RNA using the
Transcriptor First Strand cDNA Synthesis Kit with oligo
(dT) primers at 55°C for 90 min (Roche).
PCR was performed using 1 μl cDNA or genomic DNA,
10x Expand High Fidelity buffer with 15 mM MgCl2
(Roche), 200 μM dNTPs (Roche), 1 M Betaine (Sigma-
Aldrich, St. Louis, USA), 15 pmol of both forward primerMD Grade Age of death Age of onset Sex
1 1 41 35 M
1 67 47 F
2 2 80 >70 M
0 3 64 40 M
3 75 58 M
8 3 68 44 M
A 3 64 44 M
.5 3 61 NA F
2 3 41 26 F
2 NA 53 30 F
2 4 37 NA M
5 3 40 15 M
0 3 20 16 F
1 NA 11 8 F
control 64 control F
rade: neuropathological classification [28], M: male, F: female, NA: not assessed.
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AT-3′ and reverse primer HttCAGRev: 5′-TGA GGC
AGC AGC GGC TG-3′ (Eurogentec, Liege, Belgium), 3 U
Expand High Fidelity enzyme mix (Roche), and PCR grade
water to a final volume of 30 μl. The PCR program started
with a 2 min initial denaturation at 94°C, followed by
35 cycles of 15 sec denaturation at 94°C, 30 sec annealing
at 60°C, 1 min elongation at 72°C, and final elongation
step at 72°C for 7 min.
PCR products were loaded on a 2% agarose gel diluted
in Tris/Borate/EDTA (TBE) buffer. DNA gel electro-
phoresis was performed for 1 hour at 100 V. Intensities
of DNA bands were quantified using ImageJ software.
Intensity of the HTT mRNA band was divided by the
corresponding genomic DNA band to normalize for
differences in PCR efficiency due to CAG repeat length.
SNP genotyping and SNP linkage by circularization (SLiC)
The procedure for SNPs rs362273 genotyping and SNP
linkage by circularization on human brain tissue was
adapted from Liu et al. [11]. One μg of DNase-treated
total RNA, together with oligo (dT) primers, was used
for cDNA synthesis using SuperScript III First-Strand
Synthesis System (Invitrogen). To improve reverse tran-
scription of long cDNA templates, 2 M betaine and
0.6 M trehalose (both Sigma-Aldrich) were added to the
reaction mixture [25]. cDNA synthesis was performed at
42°C for 2.5 hours, followed by RNase H treatment at
37°C for 20 min. Next, 5 μl cDNA was used as template
for long-range PCR and SLiC.
Taqman SNP assay
Quantitative PCR was performed using the LightCycler
480 II (Roche), according to manufacturer’s instructions,
using a mixture containing 45 ng cDNA, 1xTaqMan
Universal PCR Master Mix, no AmpErase UNG (Ap-
plied Biosystems), 1xTaqMan SNP Genotyping Assay
(Applied Biosystems), and nuclease-free water (Ambion)
in a 20 μl reaction volume. ACTB (Applied Biosystems,
cat#Hs99999903_m1) was included as reference gene. A
standard curve was generated using pooled equal amounts
of cDNA from all samples. Quantification of the dual-
color hydrolysis of both allele-specific fluorescent re-
porter dyes, FAM (“G” allele) and VIC (“A” allele),
was performed with the LightCycler 480 SW 1.5.1
software (Roche) using the 2nd derivative method, ac-
cording to manufacturer’s instructions.
HTT antisense determination
RNA isolation as described above. PCR was performed
using 1.5 μl cDNA, 10x PCR buffer with 20 mM MgCl2
(Roche), 200 μM dNTPs (Roche), 6 pmol HTTAS_v1
primer, forward: 5′-CAC CGG GGC AAT GAA TGG-
3′, reverse: 5′-GTG CGG ATG GCA AGG ACA G-3′,2 U FastStart Taq DNA Polymerase (Roche), 1 M ethylene
glycol (Sigma-Aldrich), and PCR grade water to a final
volume of 30 μl. The PCR program started with a 3 min
initial denaturation at 95°C, followed by 40 cycles of
10 sec denaturation at 95°C, 10 sec annealing at 60°C,
10 sec elongation at 72°C, after which a final elongation
step was performed at 72°C for 7 min.
PCR products were loaded on a 3% TBE agarose gel
and bands were extracted using the NucleoSpin Gel &
PCR Clean-up kit (Machery Nagel, Düren, Germany).
To confirm the sequence of HTTAS, PCR products were
cloned into a pGEM-T Easy vector (Promega) and ana-
lyzed by Sanger sequencing using a T7-specific forward
primer.
Protein isolation
Fibroblasts were detached from the culture surface with
a 0.5% Trypsin/EDTA solution. After washing twice with
HBSS, cells were resuspended in 200 μl ice cold lysis buffer,
containing 50 mM HEPES, 50 mM NaCl, 10 mM EDTA,
10 mM DTT, 0.1% CHAPS, and 1 tablet Complete mini
protease inhibitor EDTA free (Roche) per 10 ml buffer [26].
Next, samples were sonicated 3 times 5 sec using ultra-
sound with amplitude 60 at 4°C. After 1 hour head-over-
head incubation at 4°C, extracts were centrifuged for
15 min at 10,000 × g and 4°C and supernatant was isolated.
For brain homogenates, slices from frozen unfixed
human brain tissue were collected using a sliding micro-
tome (Leica SM 2010R). Tissue was homogenized using
ceramic MagNA Lyser beads (Roche) by grinding in a
Bullet Blender (Next Advance) for 3 min at strength 8 in
lysis buffer with pH 7.2, containing 1% CHAPS, 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2PO4, 1.4 mM KH2PO4,
5 mM EDTA, 5 mM EGTA, and 1 tablet Complete mini
protease inhibitor EDTA free (Roche) per 10 ml buffer
[27]. Homogenates were incubated for 1 hour in a head-
over-head rotator at 4°C, and centrifuged for 15 min at
10,000 × g at 4°C.
Protein concentrations were determined with the
bicinchoninic acid kit (BCA) (Thermo Fisher Scientific,
Waltham, USA) using Bovine Serum Albumin (BSA) as
a standard. After addition of 5% glycerol, samples were
aliquotted, snap frozen and stored at −80°C.
Western blotting
SDS-PAGE separation of proteins was performed ac-
cording to the “shorter CAG repeats” protocol as de-
scribed previously [27]. Proteins were transferred to a
0.2 μm nitrocellulose membrane (Bio-Rad, #170-4159)
using the Trans-blot Turbo (BioRad) at 2.5A (constant)/
25 V for 10 min. Membranes were blocked for 15 min in
tris buffered saline containing 5% non-fat milk (Nutricia,
Schiphol, the Netherlands). Next, membranes were incu-
bated with primary rabbit antibody EPR5526 (Abcam,88
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htt protein, diluted 1:5000 in blocking buffer, followed
by secondary incubation with rabbit IRDye800 (LI-COR,
Lincoln, USA) diluted 1:5000 in blocking buffer. Blots
were analyzed on an Odyssey reader (LI-COR). Protein
bands corresponding to were quantified using the
Odyssey software version 3.0 (LI-COR). Background cor-
rection was performed by sampling an empty area of the
blot of the same size as the area that contained the posi-
tive protein band. Quantification of wild-type and mu-
tant htt protein relied on densitometry measurement of
both western blot bands separately. In case separation
was small, we could magnify our scanned blots using the
software’s “zoom” function to aid in a proper alignment
of the densitometry calculation boxes over both separate
bands. Wild-type and mutant htt protein expression
levels relative to total htt protein expression were calcu-
lated by dividing wild-type and mutant htt band inten-
sities with total htt band intensity (wild type +mutant).
Statistical analyses
Experiments were performed at least six times per sub-
ject (3 biological and 2 technical replicates). PCR linear-
ity was evaluated by GraphPad Prism version 6.02 by
determining the individual linear regression coefficients
(r2) of the band intensities of wild-type and mutant
HTT expression versus the number of PCR cycles.
GraphPad Prism version 6.02 was used to create whis-
ker boxplots (whiskers =min to max), showing all mean
values per sample. IBM SPSS Statistics Version 20.0.0
was used for statistical analysis. All datasets were tested
for a Gaussian distribution by visual inspection after
plotting the residuals. Significance of the pairwise differ-
ences was determined using a linear mixed model.
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Huntington disease, simple yet complex 
In 1993, the cause of Huntington disease (HD) was revealed to be one single mutation in one gene 
which allowed for the immediate development of a straightforward genetic test to determine if 
someone carried the HD-mutation [1-3]. Due to the simplicity of the mutation, hope arose that a 
therapeutic intervention against HD could soon be developed. Unfortunately, a simple cause does not 
always imply a simple cure. Since the discovery of the HTT gene, it has been well established that the 
htt protein has many cellular functions. The HD mutation leads to a cascade of pathological effects 
resulting in a variety of HD symptoms. HD combination treatments separately targeting all HD 
symptoms are complex. A single therapy that intervenes at the root-cause level in the HD pathological 
cascade is expected to alleviate all HD symptoms. In addition, such a therapy could delay HD 
symptom onset and/or prevent neurological damage when already applied during the presymptomatic 
phase of HD. Developing a cure for HD or even a therapeutic intervention that could delay symptom 
onset is the highest pinnacle of HD research [4]. Developing such therapies, which should prevent or 
block toxicity of the mutant htt protein, is challenging. The therapeutic intervention should be able to 
discriminate mutant htt from normal htt as the latter has many important functions within the cell. In 
addition, methods to deliver the therapeutic agent at areas affected by HD pathology should be 
developed. Furthermore, a reliable HD biomarker should be established to follow disease progression 
before symptom onset in order to be able to assess therapeutic efficacy in early stages of HD. Due to 
these challenges, no approved HD therapy that directly intervenes with the htt protein is available 24 
years after discovery of the HTT gene. In addition to these challenges, the idea of the mutant htt 
protein as the sole pathogenic agent in HD was challenged by de Mezer et al whom suggested effects 
of RNA toxicity [5]. 
VHH antibodies, simple yet versatile 
In 1993, the heavy chain-only antibody (HCA)-class was discovered in Camelidae. The VHH is a very 
versatile antibody fragment derived from HCA. Selection of suitable VHH from phage display banks 
is a lengthy process that involves pre-screening of recombinant clones for identical ones before 
sequencing. In chapter 2, we developed high-resolution melting curve analysis (HRMA) as a pre-
screening tool for VHH selection from Llama phage-display banks. HRMA is a widely applicable 
technique [6], capable of accurately pre-screening recombinant clones in a timely manner. HRMA was 
utilized in chapter 3, were we describe a successful selection and characterization of anti-huntingtin 
VHH antibodies. In HD research, much attention has been focussed on N-terminal htt fragments. In 
chapter 3, huntingtin-specific VHH were selected from a phage display bank originating from Llamas 
(Llama glama) immunized with an N-terminal huntingtin fragment. We showed that, next to binding 
the N-terminal htt fragment on ELISA and western blot, our VHH were also capable of precipitating 
full length htt from human brain lysates. Hence, the VHH epitope is accessible in both the N-terminal 
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htt fragment, and the full length htt protein. This makes our VHH potentially useful in studies on both 
N-terminal htt fragments and the full-length protein. For example, immunoprecipitation commonly
utilizes an antibody for antigen precipitation and another antibody to detect the precipitated antigen on
western blot. If both antibodies are from the same host species, the antibody used for precipitation
could result in strong western blot bands at around 50 kDa from the IgG heavy chain [7]. This could
obscure smaller N-terminal htt fragments. The use of camelid VHH as a precipitation antibody could
solve this issue. A drawback of using immunized banks is that the immunization process narrows the
field of binding VHH. This drawback is reflected in the homogeneity of the protein sequences from
our anti huntingtin VHH. Although immunization generally results in VHH with strong epitope
affinities, immunization does not necessarily result in VHH that give the desired biological effect. To
increase the chance of obtaining biologically relevant VHH, peptide based immunizations (e.g. with
the N17 peptide) could be performed in the future. Detailed knowledge of the structural features of htt
would aid in the development of peptides for these future immunizations. Recently, De Genst et al
used x-ray crystallography and NMR to describe how Scfv, an antibody fragment consisting of a
fusion between the variable light and heavy chain domains from a regular IgG, binding to N17 affects
htt aggregation [8]. Due to its tendency to aggregate however, mutant htt crystallization without
modifications is notoriously difficult even under microgravity conditions [9].
The huntingtin protein in post mortem human brain tissue. 
Model systems are an integral part of HD research. They offer many benefits above human subjects 
such as flexibility, speed, a uniform genetic background, controlled conditions and the possibility to 
study early pathogenic processes. For example, HD mouse models with large CAG repeats offer an 
early onset HD phenotype that allows results to be obtained within the animals life span. To be useful 
in research aimed at developing HD therapies, the model system should fit with the therapeutic 
mechanism of action. The widely used R6/2 mouse model for example, cannot be used to test HD 
therapies from which the mechanism-of-action is targeted towards more C-terminal htt domains (e.g. 
caspase-cleavage) as these are not present on the pathogenic N-terminal mutant htt fragment expressed 
in the R6/2 mouse. HD model systems do not necessarily correlate well to HD pathology in human 
brain tissue. For example, aggregation of mutant htt is a hallmark for HD in human brain tissue but is 
not detected in human-derived HD fibroblasts. Hence, interpretation of results obtained from HD 
model systems should be performed carefully and if possible, validated in human HD brain tissue. 
However next to ethical issues, using post mortem brain tissue in HD research is challenging. Possible 
effects on the htt protein due to post mortem delay (PMD) or a freeze-thaw cycle are not known and 
could influence results. In chapter 4, we have addressed how post mortem delay (PMD) affects the 
presence of N-terminal htt protein fragments in human brain tissue. Therefore we mimicked PMD 
effects in individual control and HD cases. In a recent study, PMD was mimicked in a similar way in 
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hippocampal brain tissue [10]. Blair et al reported that most variance in results is caused by 
interpersonal differences rather than PMD, and that the severity of PMD effects vary between different 
proteins (e.g. no discernible effect on actin and GAPDH, but levels of alpha tubulin are drastically 
lowered). For htt, we found similar results. Interpersonal variance on htt levels and N-terminal 
fragments was apparent, and lower htt levels were detected at longer PMD’s ( >24hr). Moreover, we 
found that PMD effects on N-terminal htt protein fragments in human brain tissue are small and can be 
defined. This allows for an accurate interpretation of western blot results. A review of previous 
western blot results on N-terminal htt fragments in human brain tissue raised an intriguing point. 
Western blot results using an anti N17-huntingtin antibody presented in chapter 4 include striatal 
tissue from an HD subject, and indicate that a 43 kDa N-terminal htt fragment is associated with PMD. 
An earlier study performed in 2001 also detected a 43 kDa N-terminal htt fragment in striatal HD 
tissue lysates using western blot [11]. However, another study performed in 2002 did not detect this 
band in striatal HD tissue lysates [12]. A review of the material and methods section reveals that the 
experimental procedures of both studies were very similar. Both utilized subjects between 55-75 years 
of age with an average PMD of 9 to 16 hr from the Harvard brain tissue resource centre but no clinical 
data of individual subjects was shown. Furthermore, western blotting by both studies was performed 
as described in [13, 14]. Although these similarities do not fully exclude the possibility that the 
difference between [11] and [12] is due to subject-to-subject variation, some other factor of variance 
(e.g. biological or technical) should be considered. 
The quantification of htt aggregates in human brain tissue is important to elucidate the role of htt 
aggregation in HD pathology. However, quantification of htt aggregates by counting them on brain 
tissue slides stained with an anti-htt antibody is a slow and subjective process that counts visible (i.e. 
larger) aggregates. In chapter 5 we present the results of a small-scale pilot study involving a filter 
retardation assay to quantify huntingtin aggregates in human brain tissue. Although more data is 
needed to fully determine the correlation between the number of aggregates in the brain and the 
amount of insoluble protein in this filter retardation assay, our results are promising. Using the filter-
binding test, we observed a correlation between the subjects polyQ-length and htt aggregation. 
Furthermore, we observed that aggregation within the cortical region was more abundant with respect 
to the striatal region in a juvenile HD-case which is in agreement with earlier studies [15, 16]. Hence, 
our results indicate that the filter-binding test could be useful for quantification of htt aggregation in 
different brain regions which will aid in further elucidating its role in HD pathogenicy.  
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Levels of normal huntingtin versus mutant huntingtin. 
Selective silencing of the mutant HTT gene is a promising potential intervention. However, complete 
selectivity towards mutant HTT without silencing of normal HTT is very difficult as the two alleles 
mainly differ in the length of their CAG sizes. Furthermore, a sufficient level of normal htt protein 
must remain for proper cellular function. Therefore, knowledge regarding basal expression levels of 
normal versus mutant HTT RNA and htt protein in human tissue is needed in order to pre-assess the 
safety and efficacy of huntingtin lowering therapies with partial selectivity towards mutant HTT. In 
chapter 6, the ratio of normal versus mutant HTT RNA and htt protein in human fibroblasts and brain 
tissue was assessed. Here, we found that the level of mutant HTT RNA was equal compared to normal 
HTT RNA in human-derived HD fibroblasts. In post-mortem human brain, levels of mutant HTT RNA 
were lower compared to normal HTT RNA. On protein level, we found that expression of the mutant 
htt protein was equal to (adult-onset HD) or lower (juvenile HD) with respect to the normal htt protein 
in both human-derived HD fibroblasts and post-mortem HD brain tissue. These results have several 
implications. First, our results suggest that some a-specific lowering of normal htt by therapeutic 
interventions aimed at lowering mutant htt protein levels is acceptable. Furthermore, it is suggested 
that adult-onset HD and juvenile HD pathologies are probably not alike, as juvenile HD symptoms 
generally present according to the Westphal-variant. Our results support this and indicate that there are 
subtle differences in RNA and protein expression levels between adult-onset HD and juvenile HD. 
This further emphasizes the importance of including HD models with a non-juvenile CAG repeat in 
molecular studies to match the adult-onset HD situation. In addition, we detected the HTT antisense 
transcript (HTTAS_v1) in a patient-derived homozygous HD fibroblast cell line. This suggests that the 
HTTAS_v1 antisense transcript with the expanded GTC repeat is not reduced in HD as suggested by 
Chung et al who were unable to detect HTTAS_v1 from the mutant HTT allele [17]. The HTTAS_v1 
antisense transcript represses HTT expression. Hence, reduced levels of HTTAS_v1 with an expanded 
GTC repeat would result in upregulation of mutant HTT expression, which is unfavourable for 
therapeutic interventions that aim to lower mutant HTT expression. Chung et al based their findings on 
a PCR encompassing the CAG/GTC repeat which is known to be technically challenging [18]. 
Coupled with the low expression level of HTTAS_v1 compared to HTT, the lack of HTTAS_v1 with an 
expanded repeat detected by Chung et al could be explained by a non-optimal PCR protocol, which 
was also acknowledged by the authors. Because we used fibroblasts from a homozygous HD subject, 
we could perform a PCR that did not encompass the repeat because both alleles were mutant, thus 
eliminating PCR artefacts. In this homozygous cell line we were able to detect HTTAS_v1 with an 
expanded GTC repeat suggesting that there is no reduction in HTTAS_v1 expression containing an 
expanded repeat. this implies that HTT expression, and thus also mutant HTT, is not elevated in HD. In 
addition, HTTAS_v1 would be an interesting prospective therapeutic agent in itself, as Chung et al 
showed the regulating effect is repeat-length dependent. Hence, overexpression of HTTAS_v1 could 
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lower the levels of mutant htt. Finally, our results from chapter 6 also suggest that htt protein 
aggregation does not affect the ratio of soluble full-length wild-type versus soluble full-length mutant 
huntingtin. Because soluble huntingtin is considered the most toxic, htt aggregation might represent a 
defensive cellular response to lower htt toxicity. Combined with literature, our results in HD fibroblast 
cells and human brain tissue suggest that htt aggregation does not affect soluble htt protein levels.  
Conclusion 
The research described in this thesis sheds light onto the huntingtin protein in the post-mortem human 
brain. The assessment of mutant and wild-type htt levels should aid in developing htt lowering 
therapies. Understanding PMD-related effects on huntingtin in post-mortem human brain supports the 
interpretation of results from brain tissue with longer PMD’s and could allow for a better 
understanding of N-terminal htt protein fragments in the human brain. The suggested filter-retardation 
assay might allow a more precise understanding of htt aggregation HD pathogenesis. The anti-
huntingtin VHH that we selected using HRMA as a companion test could find use as a scientific tool 
to track the huntingtin protein within the living cell. This thesis has contributed to knowledge 
regarding the levels, aggregation and proteolytic cleavage products of the htt protein in human brain. 
In addition, we have selected  htt specific VHH. This can contribute to obtain the ultimate goal; the 
development of a cure for HD.  
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De ziekte van Huntington (ZvH) is een autosomaal dominant overerfbare neurodegeneratieve ziekte 
gekenmerkt door motorische symptomen (chorea) en stemmingsstoornissen. Voor de ZvH is thans 
geen effectieve therapie beschikbaar. De ZvH wordt veroorzaakt door de aanwezigheid van een 
verlengde CAG repeat in het huntingtine-gen (HD-gen). Deze mutatie resulteert in de vorming van een 
mutant huntingtine eiwit met een verlengde polyQ. 
In hoofdstuk 1 wordt, na een historisch intermezzo, de frequentie, symptomen,  genetische 
achtergrond en de hersenpathologie van de ZvH beschreven. Klinisch waarneembare symptomen van 
de ZvH openbaren zich meestal op middelbare leeftijd en in zeldzame gevallen al op vroege leeftijd. 
Dit laatste wordt juveniele ZvH genoemd. Pathologie van de ZvH kenmerkt zich door ophopingen 
(aggregatie) van mutant huntingtine en een vroege specifieke atrofie van het striatum. In diermodellen 
van de ZvH en MRI-scans van personen met het HD-gen is deze ziektepathologie al pre-
symptomatisch waarneembaar. Tevens wordt ingegaan op het gevaar van het ontstaan van de novo 
zaken door intergenerationele overdracht. Vervolgens wordt ingegaan op het huntingtine-eiwit. 
Normaal huntingtine vertolkt verschillende rollen in de cel en is essentieel voor embryonale 
ontwikkeling. Uit experimenten met een knock-out muismodel blijkt dat mutant huntingtine het gemis 
van normaal huntingtine op kan vangen. Dit suggereert dat ZvH pathologie wordt gestuurd door een 
“gain-of-function” mechanisme, waarbij het mutante eiwit een of meerdere toxische additionele 
(inter)acties uitvoert. Experimenten in verschillende ZvH dier- en celmodellen geven een wisselend 
beeld met betrekking tot de expressielevels van het normale versus mutante huntingtine-eiwit. De 
vorming van met name N-terminale mutante huntingtine-fragmenten speelt een belangrijke rol in de 
ZvH pathologie. Echter, kennis van expressie-levels en N-terminale huntingtine fragmenten in humaan 
brein weefsel is beperkt. Deze kennis is belangrijk voor de ontwikkelingen van therapieën die gericht 
zijn op verlaging van het expressielevel van mutant huntingtine, of het verhinderen van de vorming 
van N-terminale huntingtine fragmenten. Als laatst wordt in hoofdstuk 1 het mogelijke nut van VHH 
antilichaamfragmenten, afgeleid van een speciaal type antilichaam afkomstig uit kameelachtigen,  als 
therapie of onderzoeksmiddel voor de ZvH besproken. In hoofdstuk 2 wordt een techniek 
gepresenteerd genaamd “high resolution meltingcurve analysis” (HRMA) welke is gebaseerd op DNA 
smeltcurve analyse. Met HMRA kunnen verzamelingen van recombinante klonen snel en nauwkeurig 
worden gescreend op identieke klonen. Deze techniek is in hoofdstuk 3 toegepast waarin de selectie 
en karakterisatie van VHH antilichaamfragmenten tegen een N-terminaal mutant huntingtine 
eiwitfragment uit een geïmmuniseerde Lama faag-display bank wordt beschreven. De VHH binden 
zowel aan een normaal als mutant N-terminaal huntingtine fragment op ELISA en Western blot, en 
zijn in staat om endogeen normaal en mutant huntingtine te immunoprecipiteren uit humaan 
breinlysaat. De VHH hebben een epitoop tussen aminozuur 49 en 148. Deze VHH kunnen gebruikt 
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worden voor verder onderzoek naar de ZvH. In hoofdstuk 4 is gekeken naar het effect van post-
mortem delay, een vries-dooi cyclus en  interpersoonlijke verschillen op het patroon van N-terminale 
huntingtine fragmenten in post-mortem humaan brein. Het effect van post-mortem delay op dit patroon 
was beperkt. Een vries-dooi cyclus op humaan breinweefsel (niet ZvH) had effect op signaalintensiteit, 
maar niet op het patroon van N-terminale huntingtine fragmenten. Het grootste effect op dit patroon 
kwam van interpersoonlijke verschillen. De resultaten van hoofdstuk 4 kunnen worden gebruikt voor 
het (her)interpreteren van studies naar N-terminale huntingtine fragmenten. Vervolgens is in 
hoofdstuk 5 een korte studie gepresenteerd naar huntingtine aggregatie in post-mortem humaan brein. 
Aggregatie is kwalitatief bepaald met behulp van immunohistochemie, en kwantitatief met behulp van 
een filter bindingstest. De resultaten van de filter bindingstest zijn op kwalitatief niveau vergelijkbaar 
met immunohistochemie. Op kwantitatief niveau liet de filterbindingstest een correlatie zien met 
polyQ lengte, en in één casus juveniele ZvH liet de filter bindingstest een significant hogere 
hoeveelheid aggregatie zien in cortex versus striatum. Deze resultaten suggereren dat de filter 
bindingstest een bruikbare tool is voor het kwantitatief bepalen van aggregatie in ZvH post-mortem 
brein. In hoofdstuk 6 is met behulp van PCR en western-blot technieken gekeken naar 
expressiehoeveelheden van normaal en mutant huntingtine mRNA en eiwit in fibroblast cellijnen 
afkomstig van ZvH patieënten, en post-mortem humaan ZvH brein. Onze resultaten tonen geen 
verschil in de hoeveelheid mRNA tussen normaal en mutant huntingtine in fibroblast cellijnen. In 
post-mortem brein was de hoeveelheid mutant huntingtine mRNA lager dan de hoeveelheid normaal 
huntingtine mRNA. Op eiwit niveau werden gelijke hoeveelheden normaal en mutant huntingtine 
gevonden in zowel fibroblast cellijnen alsmede post-mortem brein. Echter, minder mutant dan normaal 
huntingtine was aanwezig in juveniele ZvH fibroblast cellijnen en post-mortem brein weefsel. Deze 
resultaten suggereren het bestaan van subtiele verschillen in expressie tussen gewone ZvH en de 
juveniele variant. Verder onderbouwen onze resultaten de toepasbaarheid van therapieën gericht op het 
verlagen van de hoeveelheid mutant huntingtine. In hoofdstuk 7 wordt het in dit proefschrift 
beschreven onderzoek bediscussieerd in het licht van de aanwezige literatuur.  
Het in dit proefschrift beschreven onderzoek heeft het kennisveld met betrekking tot expressielevels, 
aggregatie en fragmentatie van het huntingtine eiwit in post-mortem humaan brein (iets) vergroot, en 
reikt de VHH aan als gereedschap om ook in de toekomst op innovatieve wijze onderzoek te doen met 
als uiteindelijk doel een behandeling voor de ZvH. 
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English summary 
Huntington disease (HD) is an autosomal dominant neurodegenerative disease with a variety of 
symptoms spanning from motor-related problems (chorea) to psychological issues. No effective HD 
therapy is yet available. HD is caused by expansion of a CAG repeat within the huntingtin-gene, 
resulting in a mutant huntingtin protein with an expanded polyQ. 
After a historic intermezzo, chapter 1 describes the frequency of occurrence, clinical symptoms, 
genetic background and brain pathology of HD. Onset of HD clinical symptoms typically starts around 
mid-life, but in rare cases HD symptoms occur at a young age which is referred to as juvenile HD. HD 
pathology is characterized by the presence of mutant huntingtin protein aggregations and an early 
specific atrophy of the striatum. HD pathology was detected before the onset of clinical symptoms in 
HD animal models and MRI-scans on persons who carry the HD mutation. Also, the risk of 
developing de novo HD through genetic anticipation is addressed. The huntingtin protein is discussed 
next. Huntingtin has a variety of functions within the cell and is essential for embryonic development. 
Experiments with knock-out mouse models showed that mutant huntingtin is capable of compensating 
for the loss of normal huntingtin. This suggests HD pathology exists through a “gain-of-function” 
mechanism where mutant huntingtin gains one or more toxic (inter)actions. Studies on HD animal and 
cell models show mixed results regarding the expression level of normal versus mutant huntingtin 
protein. The formation of especially N-terminal mutant huntingtin fragments is important for HD 
pathology. However, knowledge regarding protein expression levels or N-terminal huntingtin 
fragments in human brain tissue is limited. This knowledge is important with respect to- the 
development of therapies aimed at reducing expression of mutant huntingtin, or preventing the 
formation of N-terminal huntingtin fragments. At last, chapter 1 describes how VHH antibody 
fragments, derived from a special type of antibody found in camelids, could be useful as potential HD 
therapy or research tool. Chapter 2 describes “high resolution melting curve analysis”, or HRMA as a 
clone screening method. HRMA is based on DNA melting curve analysis and provides a fast and 
accurate screening of recombinant clones for the presence of identical ones. HRMA was used in 
chapter 3 that describes the selection and characterization of VHH antibody fragments against an N-
terminal mutant huntingtin fragment from an immunized Llama phage display library. The VHH binds 
normal and mutant N-terminal huntingtin fragments on ELISA and western blot and are capable of 
immunoprecipitating endogenous normal and mutant huntingtin from human HD brain lysate. The 
VHH epitope was mapped between amino acids 49 to 148 and is useful for HD research. In chapter 4, 
effects of post mortem delay, one freeze-thaw cycle and interpersonal variation on the pattern of N-
terminal huntingtin fragments in post mortem human brain were assessed. We found that the effect of 
post mortem delay is small. One freeze-thaw cycle on (non-HD) human brain tissue affected signal 
intensity, but did not affect the pattern of N-terminal htt fragments which was mainly affected by 
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interpersonal differences. Hence, the results described in chapter 4 could be used to (re)interpret study 
results regarding N-terminal huntingtin fragments. Chapter 5 presents a pilot-study into huntingtin 
aggregation in post mortem human brain tissue. Aggregation was qualitatively determined using 
immunohistochemistry, and quantitatively using a filter trap assay. On the qualitative level, results 
from the filter-trap assay are comparable with immunohistochemistry. On the quantitative level, a 
correlation was seen between the filter trap assay results and polyQ-length. Also, a significantly higher 
level of aggregation was shown with the filter trap assay within cortex compared with striatum. These 
results suggest that the filter trap assay is useful to quantify huntingtin aggregation in post mortem 
human tissue. Chapter 6 describes a PCR and western blot study into expression levels of normal 
versus mutant huntingtin RNA and protein in HD patient-derived fibroblasts and post mortem human 
HD brain tissue. Our results show no difference in mRNA quantities in fibroblasts between normal 
and mutant huntingtin. In post mortem brain tissue, quantities of mutant huntingtin mRNA was lower 
compared with normal huntingtin mRNA. On protein-level, no differences in normal versus mutant 
huntingtin was detected in either fibroblasts or post mortem brain tissue. However, when juvenile HD 
was considered, lower levels of mutant huntingtin were shown in both fibroblasts and post mortem 
brain. These results suggest that there are subtle differences in expression between regular and juvenile 
HD. Furthermore, our results support applicability of potential therapeutic interventions aimed at 
lowering mutant huntingtin levels. Chapter 7 discusses the results from this thesis against literature 
findings. 
The research described in this thesis has (modestly) broadened knowledge regarding expression levels, 
aggregation and fragmentation of the huntingtin protein in post mortem human brain tissue. Moreover, 
the VHH is presented as a new research-tool for future HD research with the ultimate goal of 
developing a cure for HD. 
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